New Stem Cell-Based Topical Solution Helps Bald People Regrow Hair – SciTechDaily

Posted on by

A clinical trial showed the ability of a stem cell-based topical solution to regrow hair in people with male/female pattern baldness.

The results of a clinical trial released today (May 18, 2020) in STEM CELLS Translational Medicinedemonstrate how a topical solution made up of stem cells leads to the regrowth of hair for people with a common type of baldness.

Androgenetic alopecia (AGA) commonly known as male-pattern baldness (female-pattern baldness in women) is a condition caused by genetic, hormonal and environmental factors. It affects an estimated 50 percent of all men and almost as many women older than 50. While it is not a life-threatening condition, AGA can lower a persons self-esteem and psychological well-being. There are a few FDA-approved medications to treat hair loss, but the most effective can have side effects such as loss of libido and erectile dysfunction. Therefore, the search continues for a safer, effective treatment.

Adipose tissue-derived stem cells (ADSCs) secrete several growth hormones that help cells develop and proliferate. According to laboratory and experimental studies, growth factors such as hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF) and platelet-derived growth factor (PDGF) increase the size of the hair follicle during hair development.

A more enriched adipose-derived stem cells-constituent extract (ADSC-CE) with stem cell proteins is obtained by disruption of the ADSC membrane using a low frequency of ultrasound wave. Credit: AlphaMed Press

Recent studies have shown that ADSCs promote hair growth in both men and women with alopecia. However, no randomized, placebo-controlled trial in humans has explored the effects and safety of adipose-derived stem cell constituent extract (ADSC-CE) in AGA. We aimed to assess the efficacy and tolerability of ADSC-CE in middle-aged patients with AGA in our study, hypothesizing that it is an effective and safe treatment agent, said Sang Yeoup Lee, M.D., Ph.D., of the Family Medicine Clinic and Research Institute of Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital in South Korea. He led the group of researchers, which also included colleagues from Pusan National University School of Medicine, Pusan National University Yangsan Hospital and T-Stem Co., Ltd.

The team recruited 38 patients (29 men and nine women) with AGA and assigned half to an intervention group that received the ADSC-CE topical solution and half as a control group that received a placebo. Twice daily, each patient applied the ADSC-CE topical solution or placebo to their scalp using their fingers.

At the end of 16 weeks, the group that received the ADSC-CEs had a significant increase in both hair count and follicle diameter, reported the studys senior author, Young Jin Tak, M.D., Ph.D.

Dr. Lee added, Our findings suggest that the application of the ADSC-CE topical solution has enormous potential as an alternative therapeutic strategy for hair regrowth in patients with AGA, by increasing both hair density and thickness while maintaining adequate treatment safety. The next step should be to conduct similar studies with large and diverse populations in order to confirm the beneficial effects of ADSC-CE on hair growth and elucidate the mechanisms responsible for the action of ADSC-CE in humans.

For the millions of people who suffer from male-pattern baldness, this small clinical trial offers hope of a future treatment for hair regrowth, said Anthony Atala, M.D., Editor-in-Chief ofSTEM CELLS Translational Medicineand director of the Wake Forest Institute for Regenerative Medicine. The topical solution created from proteins secreted by stem cells found in fat tissue proves to be both safe and effective. We look forward to further findings that support this work.

###

Reference: A Randomized, Double-blind, Vehicle-Controlled Clinical Study of Hair Regeneration Using Adipose-Derived Stem Cell Constituent Extract in Androgenetic Alopecia by Young Jin Tak, Sang Yeoup Lee, A Ra Cho and Young Sil Kim, 18 May 2020, STEM CELLS Translational Medicine.DOI: 10.1002/sctm.19-0410

AboutSTEM CELLS Translational Medicine:STEM CELLS Translational Medicine(SCTM), co-published by AlphaMed Press and Wiley, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices. SCTM is the official journal partner of Regenerative Medicine Foundation.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals:STEM CELLS, celebrating its 38th year, is the worlds first journal devoted to this fast paced field of research.The Oncologist, also a monthly peer-reviewed publication, entering its 25th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

Read the original here:

New Stem Cell-Based Topical Solution Helps Bald People Regrow Hair - SciTechDaily

Coronavirus immunity passports could create a world of ‘us and them’. But here’s why they make sense – Genetic Literacy Project

Posted on by

Dividing groups of people into us and them isnt usually a good idea, but in the scary new world of COVID-19, it makes a certain sense. Issuing immunity licenses aka passports or certificates to people whose blood contains neutralizing antibodies against the novel coronavirus may be a safer way to reopen parts of the economy than letting unchecked crowds spill onto beaches, pack into subway cars, and fill eateries, stadiums, and concert venues.

Immunity licenses would give holders certain time-limited work and social freedoms, joining larger gatherings or returning to nonessential jobs, wrote Mark A. Hall, of the Wake Forest University Schools of Law and Medicine and David M. Studdert, from Stanford University Schools of Law and Medicine, in a recent Viewpoint in JAMA.

License holders could safely:

Getting an immunity license should be free. The Coronavirus Aid, Relief and Economic Security (CARES) Act requires private and public insurers to pay for all professional SARS-CoV-2 testing, including antibody tests, and reimburse hospitals for testing uninsured patients. And licenses wont be needed indefinitely. Theyre a bridge to gradually reawaken the economy until a combination of vaccines and recovery build towards herd immunity if that happens.

The coming of immunity licenses is almost inevitable, said Ezekiel Emanuel, an oncologist and bioethicist at the University of Pennsylvania during a webinar that JAMA held, upon publication of a Viewpointhe wrote with Govind Persad, from the University of Denver.

Countries like Chile and Germany have already said they would do this. If New Zealand becomes virus-free, theyre going to only want people coming in who can demonstrate a license or do a 14-day quarantine. The UK too is discussing an immunity-based license. Its going to be travel that forces the US to adopt the idea, Emanuel said.

On the surface, the idea of distinguishing those who have recovered from those who are susceptible to infection may seem like a ticket to discrimination, a literal status symbol. Would holding a license become part of a job application, a dating profile, a metro card, or a stamp on an airline ticket like TSA precheck?

More nefariously, would not having an immunity license become like wearing a scarlet letter as Hester Prynne did in Nathaniel Hawthornes classic tale to mark her as an adulteress, or Jewish people being forced to wear yellow starsin Nazi Germany?

Dr. Emanuel doesnt see it that way:

An immunity passport enhances the liberty of those people whove been exposed to and recovered from COVID-19, but it doesnt diminish the liberty of those who are nave to the virus.

But those not holding licenses might not agree.

Comparison to Nazi Germany, which Dr. Emanuel was asked about during the webinar, is a false dichotomy, he said. We have to recognize the difference between having a star because youre Jewish and having an immunity passport because youve recovered from COVID-19. The first is whats legally called invidious discrimination taking an irrelevant factor and excluding you from benefits and rights in society, and eventually sending you to concentration camps. Thats very different from an immunity passport not based on a characteristic like race, religion, or gender, but upon recovering from an infection and becoming immune so you cant pass it on.

Emanuel compared an immunity document to the necessity of having a drivers license. Driving a car poses a lethal threat to self and others. We test people, make distinctions in gradations you need a license to drive a bus or truck or motorcycle. Similarly, with an immunity passport, you get certified, but its time-limited because we dont know how long immunity will last. Natural immunity to SARS lasts up to 2 years and to MERSup to 3 years.

Widespread use of immunity licenses also depends upon having enough accurate serology testing to reliably detect neutralizing antibodies. And we still dont know whether reinfection happens.

In a report in Nature Medicine, Joshua Weitz, from the Georgia Institute of Technology, and his team coin the term shield immunity to describe using the short-term immunity of the recently-recovered to temporarily protect the vulnerable by replacing them in parts of the outside world.

Our epidemiological intervention computational model describes ways in which serological tests used to identify individuals who have been infected by and recovered from COVID-19 could help both reduce future transmission and foster increased economic engagement, said Weitz.

The model considers a population of a specific size against shielding strategies of varying strengths to predict number of lives saved. Strength refers to the proportion of protected individuals who substitute in society for infected individuals in a particular role such as recovered health care workers.

The metrics are clear. In a population of 10 million citizens, intermediate shielding with worst-case viral transmission can reduce 71,000 deaths to 58,000. But enhanced shielding more protected people replacing vulnerable ones would cut deaths down to 20,000.

Even better would be teaming shielding with continuing some social distancing as the economy reopens.

Documents similar to immunity licenses or passports are already in use. For example, students, teachers, and educational support staff need proof of vaccination to go to school. International travelrequires a slew of vaccinations. And of course health care workers need them.

But an immunity license for COVID-19 would differ from one for, say, yellow fever or hepatitis, in three ways, Hall and Studdert argued.

First, we know so little about the new virus compared to other pathogens. Secondly, immunity is possible only through infection and recovery, not also through a vaccine. People are vaccinated against yellow fever and hepatitis B, for example.

Thirdly, the conditioned privileges could include a greater range of fundamental civil liberties and opportunities, like freedom of association, worship, work, education, and travel, wrote Hall and Studdert.

As the idea of immunity licenses gains traction, some people are antsy about waiting for the particulars to be worked out. Knowing they were sick, some individuals might start going out more, assuming immunity even if theyd never had a diagnostic PCR-based test or one for protective antibodies. Wrote Hall and Studdert:

People will begin to self-certify, with much less accuracy and credibility than if certification were official. The rapidly unfolding situation raises a host of important legal, ethical, and policy concerns that will not wait for greater scientific certainty.

Emanuel agreed. Imagine being a parent of a child going to school, or hiring a nanny. Youd do your own immunity-based passport. If it starts out haphazardly, were not going to get an organized system, he warned.

I remember back in the 1960s, in that slice of time when youngsters progressed through a series of infectious diseases measles, mumps, rubella, and chickenpox many parents intentionally exposed their kids to sick friends to get the diseases over with. The practice of pox parties diminished when the public realized that these diseases can be deadly, and with the arrival of vaccines.

Physicians today fear coronavirus parties.

We are a society based on individual rights, and we want people to make choices about risk. We allow extreme sports, skiing, bungee jumping. We allow them to drive cars. We wont get rid of pox parties entirely, but we dont want to incentivize behavior that has serious complications, said Emanuel, who admitted to having had pox parties for his now-grown sons.

But the initial thinking that kids arent likely to contract or get very sick from COVID-19 has been changing. Young people can suffer strokes. And the recent emergence of multisystem inflammatory syndromein children weeks after the acute sickness, or even in asymptomatic kids, is a good reason not to intentionally expose a child.

The fact that the virus is affecting communities of color and povertyconsiderably more than other areas is undisputed. Reasons are many: access to health care, living in crowded conditions, higher prevalence of underlying conditions that elevate risk of infection. But these higher-risk groups may also disproportionately benefit from immunity licenses.

The licenses will actually correct some disparities and even operate more as a leveler than a class divider, said Hall and Studdert. That assumes antibody testing is available to all.

Emanuel offered an example. African-Americans are 45 to 50% of the Washington, DC population, but in terms of deaths from COVID-19, they account for around 80%. It is a horrible disparity. But immunity passports would then allow these African-Americans exposed to the virus to participate in employment. Theres no discrimination in an immunity-based passport. Its based on whether youve recovered or not.

Rolling out immunity licenses will also require safeguards. They must be hard to forge or counterfeit, a nonhackable electronic certification, said Emanuel, comparing the challenge to the FAA certifying pilots. States in the end will have this responsibility, he added.

Concludes Weitz, We dont have a silver bullet. Until we have a vaccine, we will have to use a combination of strategies to control COVID-19.

Ricki Lewis is the GLPs senior contributing writer focusing on gene therapy and gene editing. She has a PhD in genetics and is a genetic counselor, science writer and author of The Forever Fix: Gene Therapy and the Boy Who Saved It, the only popular book about gene therapy. BIO. Follow her at her website or Twitter @rickilewis

The rest is here:

Coronavirus immunity passports could create a world of 'us and them'. But here's why they make sense - Genetic Literacy Project

Dyne Therapeutics Accelerates Programs in Facioscapulohumeral Muscular Dystrophy (FSHD) with Exclusive Licensing of Technologies to Target Genetic…

Posted on by

WALTHAM, Mass.--(BUSINESS WIRE)--Dyne Therapeutics, a biotechnology company pioneering life-transforming therapies for patients with serious muscle diseases, today announced the acceleration of its programs in facioscapulohumeral muscular dystrophy (FSHD) through the exclusive licensing of technologies to target the disease, as well as the appointment of leading researcher Jeffrey Statland, M.D., to its Scientific Advisory Board. Dr. Statland is an associate professor of neurology in the Department of Neurology at the University of Kansas Medical Center. He is also the co-principal investigator for ReSolve (Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD), an ongoing observational study run by the FSHD Clinical Trial Research Network (CTRN) and supported by Dyne Therapeutics.

The intellectual property exclusively licensed by Dyne targets the gene DUX4, which is the genetic basis of FSHD, and was developed by Professor Alexandra Belayew and Dr. Frdrique Coppe at the University of Mons (UMONS) Molecular Biology Laboratory in Belgium. Dyne is advancing an FSHD program using this suite of DUX4-targeting technology in combination with its proprietary FORCETM platform.

FSHD is a rare, debilitating muscle disease for which there are no approved treatments. Dyne's proprietary FORCE platform enables targeted delivery of a therapeutic inside the muscle cells of FSHD patients, where it is expected to reduce aberrant expression of the DUX4 protein and halt the loss of muscle function that characterizes FSHD. People affected by FSHD experience muscle pain and progressive skeletal muscle loss throughout the body that significantly affects their strength, mobility and quality of life. The muscle weakness often starts in the face, making it difficult to smile, and may progress to the point where affected individuals become dependent upon the use of a wheelchair for mobility.

Dyne has made a commitment to alleviating the FSHD burden for affected individuals and families. Todays announcements represent an important step forward for Dyne as we pursue our mission of delivering life-transforming therapies for serious muscle diseases, said Joshua Brumm, president and chief executive officer of Dyne. Jeff brings comprehensive insights into FSHD, including cutting-edge research into molecular and neuroimaging biomarkers that may be useful in assessing disease progression in future clinical trials. The agreement with UMONS gives us exclusive access to intellectual property to target the genetic cause of FSHD and complements our own proprietary platform for precision delivery into muscle cells.

There is a critical need for therapies to treat FSHD, which takes a debilitating physical and emotional toll on affected individuals and families, said Dr. Statland. The Dyne team is advancing FSHD research with their support of the ReSolve study and I believe their FORCE platform holds great potential. I am delighted to join Dynes Scientific Advisory Board.

Dr. Statland is an associate professor of neurology at the University of Kansas Medical Center, with both clinical and research training in neuromuscular diseases. His primary research interest is in FSHD. In addition to co-leading the ReSolve Natural History Study, Dr. Statland, with his collaborators at the University of Rochester Medical Center, is developing a disease-specific patient-reported health inventory and molecular and neuroimaging biomarkers of disease activity for future FSHD clinical trials. Dr. Statland holds a B.A. from Sarah Lawrence College, an MFA from Emerson College and an M.D. from the University of Kansas School of Medicine. He completed residency training in the Department of Neurology at the University of Kansas Medical Center and also conducted a fellowship in experimental therapeutics of neurologic disorders in the Department of Neurology at the University of Rochester Medical Center. He is board certified by the American Board of Psychiatry and Neurology.

About Dyne Therapeutics

Dyne Therapeutics is pioneering life-transforming therapies for patients with serious muscle diseases. The companys FORCETM platform delivers oligonucleotides and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision to restore muscle health. Dyne is advancing treatments for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Dyne was founded by Atlas Venture and is headquartered in Waltham, Mass. For more information, please visit http://www.dyne-tx.com, and follow us on Twitter, LinkedIn and Facebook.

Here is the original post:

Dyne Therapeutics Accelerates Programs in Facioscapulohumeral Muscular Dystrophy (FSHD) with Exclusive Licensing of Technologies to Target Genetic...

Scientists race to find a cure or vaccine for the coronavirus. Here are the top drugs in development – CNBC

Posted on by

A researcher of the Openlab genetic and cell technologies laboratory of the Kazan Federal University working with biomaterial.

Yegor Aleyev | TASS via Getty Images

Health officials and scientists across the world are racing to develop vaccines and discover effective treatments against the coronavirus, which has infected more than 4.2 million people worldwide in as little as four months, according to data compiled by Johns Hopkins University.

There are no proven, knockout treatments and U.S. health officials say a vaccine could take at least a year to 18 months.

On May 1, theFood and Drug Administration granted emergency use authorizationfor Gilead Sciences' antiviral drug remdesivir. This after a government-run clinical trial found Covid-19 patients who took remdesivir usually recovered after 11 days. That is four days faster than those who didn't take the drug. The EUA means doctors in the U.S. will be allowed to use remdesivir on patients hospitalized with Covid-19 even though it has not been formally approved by the agency.

Even if the drug wins final approval, infectious disease specialists and scientists say researchers will need an arsenal of medications to fight this respiratory virus, which can also attack the cardiovascular, nervous, digestive and other major systems of the body.

Below is a list of the leading vaccines and drugs in development to battle Covid-19.

Nicolas Asfouri | AFP | Getty Images

Moderna

The National Institutes of Health, an agency within the Department of Health and Human Services, has been fast-tracking work with biotech company Moderna to develop a vaccine to prevent Covid-19.The company began the first phase 1 human trialon45 volunteers testing a vaccine to prevent the disease in March and has been approved to soon start its phase 2, which would expand the testing to 600 people, by late May or June. If all goes well, its vaccine could be in production as early as July.

Scientist Xinhua Yan works in the lab at Moderna in Cambridge, Massachusetts, on Feb. 28, 2020. Moderna has developed the first experimental coronavirus medicine, but an approved treatment is more than a year away.

David L. Ryan | Boston Globe | Getty Images

Moderna's potential vaccine contains genetic material called messenger RNA, or mRNA, that was produced in a lab. The mRNA is a genetic code that tells cells how to make a protein and was found in the outer coat of the new coronavirus, according to researchers at the Kaiser Permanente Washington Health Research Institute. The mRNA instructs the body's own cellular mechanisms for making proteins to create those that mimic the virus proteins, thereby producing an immune response.

Johnson & Johnson

Johnson & Johnson began Covid-19 vaccine development in January. J&J's lead vaccine candidate will enter a phase 1 human clinical study by September, the company announced in March, and clinical data on the trial is expected before the end of the year. If the vaccine works well, the company said it could produce600 million to 900 million doses by April 2021.

The company said it is using the same technologies it used to make its experimental Ebola vaccine, which was provided to people in the Democratic Republic of Congo in late 2019. It involves combing genetic material from the coronavirus with a modified adenovirus that is known to cause common colds in humans.

Inovio Pharmaceutical

Inovio began its early stage clinical trials for a potential vaccine on April 6,making it the second potential Covid-19 vaccine to undergo human testing after Moderna. It says it will enroll up to 40 healthy adult volunteers in Pennsylvaniaand Missouri and expects initial immune responses and safety data by late summer. Inovio made its potential vaccine by adding genetic material of the virus inside synthetic DNA, which researchers hope will cause the immune system to make antibodies against it.

Oxford University

A coronavirus vaccine developed by researchers at Oxford University began phase 1 human trials on April 23. British Health Minister Matt Hancock saidthat he wouldprovide 20 million, ($24.5 million), to help fund the Oxford project. The team said it aims to produce 1 million doses by September.

General view of the sign for University of Oxford, Old Road Campus and Trials clinic on May 02, 2020 in Oxford, England.

Catherine Ivill | Getty Images

Oxford researchers are calling their experimental vaccineChAdOx1 nCoV-19, and it's a kind ofrecombinant viral vector vaccine. Like J&J's team, the researchers will place genetic material from the coronavirus into another virus that's been modified. They will then inject the virus into a human, hoping to produce an immune response.

Pfizer

Pharmaceutical giant Pfizer,which is working alongside German drugmaker BioNTech, began testing an experimental vaccine to combat the coronavirus in the U.S. on May 5.The U.S.-based drugmaker hopes to produce "millions" of vaccines by the end of this year and expects to increase to "hundreds of millions" of doses next year. The experimental vaccine uses mRNA technology, similar to Moderna. The mRNA is a genetic code that tells cells what to build in this case, an antigen that may induce an immune response for the virus.

In this photo illustration the American multinational pharmaceutical corporation Pfizer logo seen displayed on a smartphone with a computer model of the COVID-19 coronavirus on the background.

Budrul Chukrut | SOPA Images | Getty Images

Sanofi and GSK

Sanofi and GSKannouncedApril14 that they had entered an agreement to jointly create a Covid-19 vaccineby the end of next year.The companies plan to start clinical trials in the second half of 2020 and, if successful, produce up to 600 million doses next year. To make it, Sanofi said it will repurpose its SARS vaccine candidate that never made it to market while GSK will provide pandemic adjuvant technology, which is meant to enhance the immune response in vaccines.

Novavax

Novavax announced on April 8 it found a coronavirus vaccine candidate and would start human trials in May with preliminary results expected in July. The potential vaccine, which is being calledNVX-CoV2373, is usingadjuvant technology and will attempt to neutralize the so-called spike protein, found on the surface of the coronavirus, which is used to enter the host cell.

Vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir are capped at a Gilead Sciences facility in La Verne, California, U.S. March 18, 2020. Picture taken March 18, 2020.

Gilead Sciences Inc | Reuters

Gilead Sciences

The FDA granted emergency use authorization for Gilead's remdesivir drug to treat Covid-19 on May 1. The National Institute of Allergy and Infectious Diseases released results from its study showing patients who took remdesivir usually recovered faster than those who didn't take the drug. Even though remdesivir was granted for emergency use, there are still several ongoing clinical trials testing whether it's effective in stopping the coronavirus from replicating.

Remdesivir has shown some promise in treating SARS and MERS, which are also caused by coronaviruses. Some health authorities in the U.S., China and other parts of the world have been using remdesivir, which was tested as a possible treatment for the Ebola outbreak, in hopes that the drug can improve the outcomes for Covid-19 patients. The company said it expects to produce more than 140,000 rounds of its 10-day treatment regimen by the end of May and anticipates it can make 1 million rounds by the end of this year.

New York state and others

Hydroxychloroquine is a decades-old malaria drug touted by PresidentDonald Trumpas a potential "game-changer."

The drug is proven to work in treating Lupus and rheumatoid arthritis, but not Covid-19. A handful of small studies on its use in coronavirus patients published in France and China had raised hope that the drug might help fight the virus. However, hydroxychloroquine, which is available as a generic drug and is also produced under the brand name Plaquenil by French drugmaker Sanofi, can have serious side effects, including muscle weakness and heart arrhythmia.

A bottle of Prasco Laboratories Hydroxychloroquine Sulphate is arranged for a photograph in the Queens borough of New York, U.S., on Tuesday, April 7, 2020.

Christopher Occhicone | Bloomberg | Getty Images

The FDA issueda warning against takingthe drug outside a hospital or formal clinical trial setting after it became aware of reports of "serious heart rhythm problems" in patients.

On March 24, researchers at NYU Langone in New York launchedone of the nation's largest hydroxychloroquine clinical studiesafter federal health regulators fast-tracked approvals for coronavirus research, allowing scientists across the nation to skip through months of red tape. It's one of more than a dozen formal studies in the U.S. looking at treatments for the coronavirus,according to ClinicalTrials.gov.

But the early results aren't so promising. An observational study published in thejournal JAMA Network Open on Monday and run by the New York State Department of Health, in partnership with the University of Albany, found that it didn't help coronavirus patients. Worse yet, when taken with azithromycin which French researchers credited with speeding recovery times it put patients at significantly higher risk of cardiac arrest.

Zhejiang Hisun Pharmaceutical

Favipiravir is an anti-flu drug sold byFujifilm Holding under the name Avigan. Researchers in China are testing the drug to see if it's effective in fighting the coronavirus. Most of favipiravir's preclinical data is derived from its influenza and Ebolaactivity; however, the agent also demonstrated broad activity against other RNA viruses, according to researchers in Japan.

Regeneron and Sanofi

Regeneron and Sanofi started clinical trials of rheumatoid arthritis drug Kevzara in Covid-19 patients in March.The drug inhibits a pathway thought to contribute to the lung inflammation in patients with the most severe forms of Covid-19.

The companies announced last month that Kevzara showed promise for treating the sickest coronavirus patients in a clinical trial but it wasn't beneficial for patients with less-advanced disease, prompting the companies to stop testing the medicine in that group.

Eli Lilly

Eli Lilly, in partnership with National Institute of Allergy and Infectious Diseases, is seeing if its rheumatoid arthritis drugbaricitinib is effective against the coronavirus.The company theorizes that baricitinib's anti-inflammatory effects could curb the body's reaction to the virus.

Eli Lilly, AstraZeneca and Regeneron

While some drugmakers are looking for vaccines to stop the virus, Eli Lilly, AstraZeneca and Regeneron, among other companies, are working on so-called antibody treatments, which are made to act like immune cells and may provide protection after exposure to the virus. Earlier this month,Regeneron said its treatment could be available for use by the end of this summer or fall.

Original post:

Scientists race to find a cure or vaccine for the coronavirus. Here are the top drugs in development - CNBC

WHITEHALL ANALYTICA THE AI SUPERSTATE: Part 2 Is COVID-19 Fast-Tracking a Eugenics-Inspired Genomics Programme in the NHS? – Byline Times

Posted on by

Nafeez Ahmed explores the troubling implications and assumptions of the Governments AI-driven gene programme.

In Part 1 of this investigation, I looked at how the convergence of an AI Superstate and corporate interests with health data lies at the heart of a new frontier for profit and surveillance. But the Governments response during the COVID-19 pandemic has revealed something even more profoundly disturbing: a fascination with genomics which moves from a merely descriptive tool to something so prescriptive it verges on eugenics.

The NHSX app is simply one project with a questionable design which appears to result from the Governments much wider project to remake the NHS.

At the core of the new NHSX AI drive is the goal of predictive, preventive, personalised and participatory medicine, according to an NHSX document published in October 2019. Pivotal to this AI-driven transformation is genetics:

Key to unlocking the benefits of precision medicine with AI is the use of genomic data generated by genome sequencing. Machine learning is already being used to automate genome quality control. AI has improved the ability to process genomes rapidly and to high standards and can also now help improve genome interpretation.

The NHS Genomic Medicine Service is starting with a focus on cancer, rare and inherited diseases,but its broader goal is far more comprehensive. Initially, the hope is that genomics will expand to cover other areas, such as pharmacogenomics, which looks at how an individuals genes influence a particular biological process that mediates the effects of a medicine, according to The Pharmaceutical Journal.

But the end-goal is to convert the NHS into a health service oriented fundamentally around the role of genetics in disease. The aspiration is that from 2020, and by 2025, genomic medicine will be an embedded part of routine care to enable better prediction and prevention of disease and fewer adverse drug reactions. The GMS aims to complete five million genomic analyses and five million early disease cohorts over the next five years.

By 2025, genomic technologies will be embedded through multiple clinical pathways and included as a fundamental part of clinical training. As a result, it is hoped that there will be a new taxonomy of medicine based on the underlying drivers of disease.

But, this entire premise is deeply questionable. There is little evidence that the underlying drivers of disease are primarily genetic.

Last December, a study in the journal PLOS One found that genetics usually explains no more than 5-10% of the risk for several common diseases. The study examined data from nearly 600 earlier studies identifying associations between common variations in the DNA sequence and more than 200 medical conditions. But its conclusion was stark: more than 95% of diseases or disease risks including Alzheimers, autism, asthma, juvenile diabetes, psoriasis, and so on could not be predicted accurately from the DNA sequence. A separate meta-analysis of two decades of DNA science corroborated this finding.

The implication is startling: that the entire premise for the billions of pounds this Government is investing in building a new privatised NHS infrastructure for AI-driven genomic medicine is scientifically unfounded.

The obsession with genetics can be traced directly back to the Prime Ministers chief advisor, Dominic Cummings.

Cummings set out his vision for the NHS in a February 2019 blog, which although previously reported on has not been fully appreciated for its astonishingly direct implications. While focusing on disease risk, the blog flagged-up Cummings hopes that a new NHS genomics prediction programme would ultimately allow the UK to, not just prevent diseases, but to do so before birth in effect a nod toward the selective breeding techniques at the core of eugenics.

They are using the COVID-19 crisis to erect a corporate superstate powered by mass surveillance and AI. Their grim ambition is to reach into the very DNA of every British citizen.

His vision for what a genomics-focused NHS would look like bears startling resemblance to the core ideas of eugenics the discredited pseudoscience aiming to improve the genetic quality of a human population by selecting for superior groups and excluding those with inferior genes. Its worst manifestations were exemplified by the Nazis.

In the blog, Cummings wrote:

Britain could contribute huge value to the world by leveraging existing assets, including scientific talent and how the NHS is structured, to push the frontiers of a rapidly evolving scientific field genomic prediction. He called for free universal SNP [single-nucleotide polymorphis] genetic sequencing as part of a shift to genuinely preventive medicine, to be rolled-out across the UK. This approach holds the promise of revolutionising healthcare in ways that give Britain some natural advantages over Europe and America.

Later in the post, Cummings allowed himself to speak more directly to what natural advantages could actually entail. He claimed that a combination of AI-driven machine learning with very large genetic sampling could enable the precise prediction of complex traits such as general intelligence and most diseases.

The two scientists Cummings cited as the primary sources for his vision were educational psychologist Robert Plomin and physicist Steven Hsu.

Plomin, described by Cummings as the worlds leading expert on the subject, is a renowned scientist. But he also has a history of association with the eugenics movement, according to Dr David King, founder of Human Genetics Alert and previously a molecular biologist. (Sir David King, the former chief scientific adviser to the UK Government, has also criticised the genome sequencing goldrush).*

When The Bell Curve a book advocating the genetic inferiority of African Americans was published, Plomin was a key signatory to a statement defending the science behind the book, explained Dr David King in a paper for the non-profit watchdog Human Genetics Alert. The statement carefully avoided explicitly endorsing The Bell Curves racist conclusions (aptly summarised by Francis Wheen as black people are more stupid than white people: always have been, always will be. This is why they have less economic and social success), while failing to repudiate them. Plomins fellow co-signatories included several self-proclaimed scientific racists, Philippe Rushton and Richard Lynn. Plomin has also published papers with the American Eugenics Society and spoken at several meetings of the British Eugenics Society (the latter rebranded itself as the Galton Institute in 1989) both of which advocated racial science.

In December 2013, Plomin was called as an expert witness to the House of Commons Education Select Committee, where he called for the Government to focus on the heritability of educational attainment. Twenty-five minutes into the session, Dominic Raab who as Foreign Secretary and First Secretary has stood in for Boris Johnson during his period of absence due to COVID-19 prompted Plomin to focus more specifically on explaining his views about genetics, intelligence and socio-economic status.

Just two months before Plomins parliamentary testimony, a 237-page dossier by Cummings then a top advisor to Education Secretary Michael Gove was leaked to the press. The paper claimed that genetics plays a bigger role in a childs IQ than teaching and called for giving specialist education as per Eton to the top 2% in IQ. Pete Shanks of the Centre for Genetics and Society described Cummings policy proposal as a blatantly eugenic association of genes with intelligence, intelligence with worth, and worth with the right to rule.

The Cummings dossier which cites Plomin extensively further reveals that, according to Cummings, he had invited Plomin into the DfE [Department for Education] to explain the science of IQ and genetics to officials and ministers.

The Education Select Committees report shows that, at the time of Plomins testimony, the Government was resistant to these views. But, the position appears to have changed since then, with figures such as Cummings, Raab and Gove now at the seat of power under Prime Minister Boris Johnson.

Plomin would go on to work with Steven Hsu, who was involved in a major Chinese genome sequencing project based on thousands of samples from very high-IQ people around the world. The goal was to identify genes that can predict intelligence. Hsu went on to launch his own company, Genomic Prediction. In slide presentations about his work from 2012, Hsu approvingly quoted British eugenicist Ronald Fisher, closing his slides with the following quotation: but such a race will inevitably arise in whatever country first sees the inheritance of mental characters elucidated. Hsus slides, wrote David King, include plans for a eugenic breeding scheme using embryo selection to improve the overall IQ of the population.

Yet, on his blog, Cummings confirmed that Hsu has recently attended a conference in the UK where he presented some of these ideas to UK policy-makers. Among the ideas Hsu presented to Cummings colleagues in Government was that the UK could become the world leader in genomic research by combining population-level genotyping with NHS health records. Hsu further claimed that risk prediction for common diseases was already available to guide early interventions that save lives and money.

Hopefully the NHS and Department for Health will play the Gretzky game, take expert advice from the likes of Plomin and Hsu and take this opportunity to make the UK a world leader in one of the most important frontiers in science, enthused Cummings.

Plomins claim that intelligence is determined primarily by genes contradicts a vast body of scientific literature, and is largely overblown. One of the latest studies debunking Cummings hopes was led by the University of Bristol and published in March. Based on a sample size of 3,500 children, the study found that polygenic scores (which combine information from all genetic material across the entire genome) have limited use for accurately predicting individual educational performance or for personalised education.

The study did not dismiss a role for genes outright, noting genetic scores modestly predictededucational achievement. The problem was that these predictions were less accurate than using standard information known to predicteducational outcomes, such as achievement at younger ages, parents educational attainment or family socio-economic position.

Last November, Hsus Genomic Prediction began touting new report cards to its customers. The cards displayed alleged results of genetic tests containing warnings that embryos might have low intelligence, grow up to be short, or have other conditions such as diabetes. But, according to the MIT Technology Review, the company has struggled both to validate its predictions and to interest fertility centres in them. In the month prior to Hsus grand announcement, the first major study to test the empirical viability of screening embryos, led by statistical geneticist Shai Carmi of the Hebrew University of Jerusalem, concluded that the technology is not plausible.

The lack of scientific substantiation has not stopped Cummings from suggesting a more interventionist vision for the NHS, which could be accused of paving the way for a new form of eugenics. In his February 2019 blog, he wrote: We can imagine everybody in the UK being given valuable information about their health for free,truly preventive medicinewhere we target resources at those most at risk, and early (evenin utero) identification of risks. This passage appears to nod to the core eugenics notion of selective breeding using embryo selection. Cummings even went further to endorse the goal of editing genes to fix problems.

In a further telling but slightly more well-known passage, Cummings characterised the genomics programme as a precursor to more realistic views about IQ and social mobility: It ought to go without saying that turning this idea into a political/government success requires focus on A) the NHS, health, science, NOT getting sidetracked into B) arguments about things like IQ and social mobility. Over time, the educated classes will continue to be dragged to more realistic views on (B) but this will be a complex process entangled with many hysterical episodes. (A) requires ruthless focus.

This passage affirms that Cummings approach is deliberately deceptive. The focus on health and the NHS is revealed as a cover for a longer-term vision to usher in more realistic views about things like IQ and social mobility. The passage also lifts the rock on Cummings weakest point that he fears that public attention on these more realistic views could sidetrack the broader strategy before it reaches fruition.

In the words of Dr David King, Cummings deference to Hsu, who openly advocated eugenics breeding programmes, suggests that the Prime Ministers chief advisor clearly favours this strategy for Britain; of course, this is precisely what all the European countries were trying to achieve in the heyday of eugenics to overcome their imperialist competitors by improving the national stock.

This, it seems, is the essence of Cummings ambition to use the NHS genomics prediction programme as a mechanism to provide Britain natural advantages over Europe and America.

And in this context, it is impossible to ignore the implications of Cummings appointment of Andrew Sabisky to a senior role advising Boris Johnson. When Johnsons spokespeople were asked repeatedly whether the Prime Minister would condemn Sabiskys sympathies for racist eugenics, he repeatedly refused. Sabisky later stepped away from the role.

The COVID-19 pandemic has now provided the Government with the opportunity to double down on its goals of extending genome sequencing across the UK population.

While genomic sequencing of the Coronavirus is undoubtedly an important scientific task to map and understand it, the crisis fits neatly into Cummings call for a ruthless focus on the NHS as a vehicle for Britains genetic enhancement.

On 23 March, when the UK finally instituted a lockdown at least three weeks after being informed that hundreds of thousands of people (and potentially up to a million) people were at risk of death from its previous policy of herd immunity, the Government launched a new scientific research consortium coordinated by Cambridge University along with the Wellcome Sanger Institute, the NHS and Public Health England.

The consortium would gather samples from patients confirmed with COVID-19 and send them to genetic sequencing centres across the country to analyse the whole genetic code of the samples. The project was billed breathlessly as an essential step in being able to control the pandemic and prevent further spread.

Unsurprisingly, it has done no such thing. Instead, six weeks later, the UK has ended up with the highest COVID-19 fatality rate in Europe.

As the death toll approaches the same level of British civilian casualties during the Second World War, the Governments strategy has privileged ambiguous, extortionate high technology solutions, pouring hundreds of millions of pounds into powerful private sector players with no transparency or due process. Meanwhile, traditional, proven, public health strategies such as better border controls, or extensive contact tracing and testing by scaling up local capacity, were inexplicably delayed for months.

On 13 March, the Government launched a new partnership between the NHS, Genomics England, the GenOMICC consortium, and US biotech giant Illumina, to conduct a nationwide human whole genome sequencing study targeting COVID-19 patients in 170 intensive care units.

The Governments new genome sequencing partner, Illumina, has previously produced genetic sequencing systems marketed to police agencies in China to facilitate its genetic profiling of the minority Uyghur population in Xinjang the largest system of discriminatory, ethnically-targeted biometric surveillance using DNA ever created.

It is difficult to avoid the conclusion that Dominic Cummings and his fellow ideologues in Government are hell-bent on pursuing a pseudo-scientific vision that has been years in the making.They are using the COVID-19 crisis to erect a corporate superstate powered by mass surveillance and AI. Their grim ambition is to reach into the very DNA of every British citizen.

Dominic Cummings was contacted for this article, but is yet to reply.

*This article was corrected to remove a confusion between Sir David King, the former government chief scientific adviser, and Dr David King, the molecular biologist who isthefounder and Director of Human Genetics Alert.

Continued here:

WHITEHALL ANALYTICA THE AI SUPERSTATE: Part 2 Is COVID-19 Fast-Tracking a Eugenics-Inspired Genomics Programme in the NHS? - Byline Times

CRISPR And CRISPR-Associated (Cas) Genes Market Size, Share, Trends and Forecast 2026 by Major Players and Business Opportunities Caribou…

Posted on by

The report offers in-depth analysis of the global CRISPR And CRISPR-Associated (Cas) Genes market taking into account market dynamics, segmentation, geographical expansion, competitive landscape, and various other key aspects. The market analysts who have prepared the report have thoroughly studied the global CRISPR And CRISPR-Associated (Cas) Genes market and have offered reliable and accurate data. They understand the needs of the industry and the clients, which makes it easy for them to focus on the aspects, which the end users have been looking for.

Major Key Player Operating in this Report are: Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon

Get the Sample of this [emailprotected]https://www.qyresearch.com/sample-form/form/1434599/global-crispr-and-crispr-associated-cas-genes-market

The report analyses the current trends, growth opportunities, competitive pricing, restraining factors, and boosters that may have an impact on the overall dynamics of the global CRISPR And CRISPR-Associated (Cas) Genes market. The report analytically studies the microeconomic and macroeconomic factors affecting the global CRISPR And CRISPR-Associated (Cas) Genes market growth. New and emerging technologies that may influence the global CRISPR And CRISPR-Associated (Cas) Genes market growth are also being studied in the report.

The market experts also offer best possible service and recommendations to the customers. This report can surely act as a resourceful tool for the companies, investors, and executives to become equipped and take sound and effective decisions. This will eventually help them stay ahead of the curve and gain maximum profits.

Segmental Analysis

The analysts have thoroughly studied all the segments including product type, application, and region. The report provides comprehensive analysis of the contribution of the segments to the overall market size. Moreover, the experts have predicted each segments growth potential, which may assist the clients to plan their future activities. The regional analysis mentioned in the report gives a clear cut understanding to the market participants regarding the present as well as future scenario of the global CRISPR And CRISPR-Associated (Cas) Genes market in key regions.

Segment By Type:

, Genome Editing, Genetic engineering, gRNA Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops, Cell Line Engineering

Segment By Application:

, Biotechnology Companies, Pharmaceutical Companies, Academic Institutes, Research and Development Institutes Key Players: The Key manufacturers that are operating in the

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global CRISPR And CRISPR-Associated (Cas) Genes industry. In order to fulfill the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global CRISPR And CRISPR-Associated (Cas) Genes market include Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon

Key queries related to the global CRISPR And CRISPR-Associated (Cas) Genes market addressed in the report:

While planning the strategic initiatives, market participants come across various questions and uncertainties. This report resolves various queries that most market players have regarding the global CRISPR And CRISPR-Associated (Cas) Genes market. Does the global CRISPR And CRISPR-Associated (Cas) Genes market have growth potential? What are the growth opportunities for the new entrants in the global CRISPR And CRISPR-Associated (Cas) Genes market? Who are the leading manufacturers operating in the global CRISPR And CRISPR-Associated (Cas) Genes market? Will they maintain their dominance in future? What are the key strategies that market players may adopt to strengthen their presence in the global CRISPR And CRISPR-Associated (Cas) Genes market? How will the competitive scenario undergo a change in years to come? What are the emerging trends that may influence the growth of the global CRISPR And CRISPR-Associated (Cas) Genes market? What are the factors that may hamper the global CRISPR And CRISPR-Associated (Cas) Genes market growth in the years ahead? Which product type segment is expected to exhibit promising growth in the near future? What application is anticipated to grab a major share in the global CRISPR And CRISPR-Associated (Cas) Genes market? Which region is likely to emerge as a lucrative regional market in the forthcoming years?

Get Customized Report in your Inbox within 24 hours @https://www.qyresearch.com/customize-request/form/1434599/global-crispr-and-crispr-associated-cas-genes-market

CRISPR And CRISPR-Associated (Cas) Genes Market Table of Content

Table of Contents 1 CRISPR And CRISPR-Associated (Cas) Genes Market Overview1.1 Product Overview and Scope of CRISPR And CRISPR-Associated (Cas) Genes1.2 CRISPR And CRISPR-Associated (Cas) Genes Segment by Type1.2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Growth Rate Comparison by Type (2021-2026)1.2.2 Genome Editing1.2.3 Genetic engineering1.2.4 gRNA Database/Gene Librar1.2.5 CRISPR Plasmid1.2.6 Human Stem Cells1.2.7 Genetically Modified Organisms/Crops1.2.8 Cell Line Engineering1.3 CRISPR And CRISPR-Associated (Cas) Genes Segment by Application1.3.1 CRISPR And CRISPR-Associated (Cas) Genes Sales Comparison by Application: 2020 VS 20261.3.2 Biotechnology Companies1.3.3 Pharmaceutical Companies1.3.4 Academic Institutes1.3.5 Research and Development Institutes1.4 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size Estimates and Forecasts1.4.1 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue 2015-20261.4.2 Global CRISPR And CRISPR-Associated (Cas) Genes Sales 2015-20261.4.3 CRISPR And CRISPR-Associated (Cas) Genes Market Size by Region: 2020 Versus 2026 2 Global CRISPR And CRISPR-Associated (Cas) Genes Market Competition by Manufacturers2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Market Share by Manufacturers (2015-2020)2.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Share by Manufacturers (2015-2020)2.3 Global CRISPR And CRISPR-Associated (Cas) Genes Average Price by Manufacturers (2015-2020)2.4 Manufacturers CRISPR And CRISPR-Associated (Cas) Genes Manufacturing Sites, Area Served, Product Type2.5 CRISPR And CRISPR-Associated (Cas) Genes Market Competitive Situation and Trends2.5.1 CRISPR And CRISPR-Associated (Cas) Genes Market Concentration Rate2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)2.6 Manufacturers Mergers & Acquisitions, Expansion Plans2.7 Primary Interviews with Key CRISPR And CRISPR-Associated (Cas) Genes Players (Opinion Leaders) 3 CRISPR And CRISPR-Associated (Cas) Genes Retrospective Market Scenario by Region3.1 Global CRISPR And CRISPR-Associated (Cas) Genes Retrospective Market Scenario in Sales by Region: 2015-20203.2 Global CRISPR And CRISPR-Associated (Cas) Genes Retrospective Market Scenario in Revenue by Region: 2015-20203.3 North America CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Country3.3.1 North America CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.3.2 North America CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.3.3 U.S.3.3.4 Canada3.4 Europe CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Country3.4.1 Europe CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.4.2 Europe CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.4.3 Germany3.4.4 France3.4.5 U.K.3.4.6 Italy3.4.7 Russia3.5 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Region3.5.1 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Sales by Region3.5.2 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Sales by Region3.5.3 China3.5.4 Japan3.5.5 South Korea3.5.6 India3.5.7 Australia3.5.8 Taiwan3.5.9 Indonesia3.5.10 Thailand3.5.11 Malaysia3.5.12 Philippines3.5.13 Vietnam3.6 Latin America CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Country3.6.1 Latin America CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.6.2 Latin America CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.6.3 Mexico3.6.3 Brazil3.6.3 Argentina3.7 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Country3.7.1 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.7.2 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.7.3 Turkey3.7.4 Saudi Arabia3.7.5 U.A.E 4 Global CRISPR And CRISPR-Associated (Cas) Genes Historic Market Analysis by Type4.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Market Share by Type (2015-2020)4.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Market Share by Type (2015-2020)4.3 Global CRISPR And CRISPR-Associated (Cas) Genes Price Market Share by Type (2015-2020)4.4 Global CRISPR And CRISPR-Associated (Cas) Genes Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Global CRISPR And CRISPR-Associated (Cas) Genes Historic Market Analysis by Application5.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Market Share by Application (2015-2020)5.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Market Share by Application (2015-2020)5.3 Global CRISPR And CRISPR-Associated (Cas) Genes Price by Application (2015-2020) 6 Company Profiles and Key Figures in CRISPR And CRISPR-Associated (Cas) Genes Business6.1 Caribou Biosciences6.1.1 Corporation Information6.1.2 Caribou Biosciences Description, Business Overview and Total Revenue6.1.3 Caribou Biosciences CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.1.4 Caribou Biosciences Products Offered6.1.5 Caribou Biosciences Recent Development6.2 Addgene6.2.1 Addgene CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.2.2 Addgene Description, Business Overview and Total Revenue6.2.3 Addgene CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.2.4 Addgene Products Offered6.2.5 Addgene Recent Development6.3 CRISPR THERAPEUTICS6.3.1 CRISPR THERAPEUTICS CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.3.2 CRISPR THERAPEUTICS Description, Business Overview and Total Revenue6.3.3 CRISPR THERAPEUTICS CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.3.4 CRISPR THERAPEUTICS Products Offered6.3.5 CRISPR THERAPEUTICS Recent Development6.4 Merck KGaA6.4.1 Merck KGaA CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.4.2 Merck KGaA Description, Business Overview and Total Revenue6.4.3 Merck KGaA CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.4.4 Merck KGaA Products Offered6.4.5 Merck KGaA Recent Development6.5 Mirus Bio LLC6.5.1 Mirus Bio LLC CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.5.2 Mirus Bio LLC Description, Business Overview and Total Revenue6.5.3 Mirus Bio LLC CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.5.4 Mirus Bio LLC Products Offered6.5.5 Mirus Bio LLC Recent Development6.6 Editas Medicine6.6.1 Editas Medicine CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.6.2 Editas Medicine Description, Business Overview and Total Revenue6.6.3 Editas Medicine CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.6.4 Editas Medicine Products Offered6.6.5 Editas Medicine Recent Development6.7 Takara Bio USA6.6.1 Takara Bio USA CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.6.2 Takara Bio USA Description, Business Overview and Total Revenue6.6.3 Takara Bio USA CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.4.4 Takara Bio USA Products Offered6.7.5 Takara Bio USA Recent Development6.8 Thermo Fisher Scientific6.8.1 Thermo Fisher Scientific CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.8.2 Thermo Fisher Scientific Description, Business Overview and Total Revenue6.8.3 Thermo Fisher Scientific CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.8.4 Thermo Fisher Scientific Products Offered6.8.5 Thermo Fisher Scientific Recent Development6.9 Horizon Discovery Group6.9.1 Horizon Discovery Group CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.9.2 Horizon Discovery Group Description, Business Overview and Total Revenue6.9.3 Horizon Discovery Group CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.9.4 Horizon Discovery Group Products Offered6.9.5 Horizon Discovery Group Recent Development6.10 Intellia Therapeutics6.10.1 Intellia Therapeutics CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.10.2 Intellia Therapeutics Description, Business Overview and Total Revenue6.10.3 Intellia Therapeutics CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.10.4 Intellia Therapeutics Products Offered6.10.5 Intellia Therapeutics Recent Development6.11 GE Healthcare Dharmacon6.11.1 GE Healthcare Dharmacon CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.11.2 GE Healthcare Dharmacon CRISPR And CRISPR-Associated (Cas) Genes Description, Business Overview and Total Revenue6.11.3 GE Healthcare Dharmacon CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.11.4 GE Healthcare Dharmacon Products Offered6.11.5 GE Healthcare Dharmacon Recent Development 7 CRISPR And CRISPR-Associated (Cas) Genes Manufacturing Cost Analysis7.1 CRISPR And CRISPR-Associated (Cas) Genes Key Raw Materials Analysis7.1.1 Key Raw Materials7.1.2 Key Raw Materials Price Trend7.1.3 Key Suppliers of Raw Materials7.2 Proportion of Manufacturing Cost Structure7.3 Manufacturing Process Analysis of CRISPR And CRISPR-Associated (Cas) Genes7.4 CRISPR And CRISPR-Associated (Cas) Genes Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers8.1 Marketing Channel8.2 CRISPR And CRISPR-Associated (Cas) Genes Distributors List8.3 CRISPR And CRISPR-Associated (Cas) Genes Customers 9 Market Dynamics 9.1 Market Trends 9.2 Opportunities and Drivers 9.3 Challenges 9.4 Porters Five Forces Analysis 10 Global Market Forecast10.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Estimates and Projections by Type10.1.1 Global Forecasted Sales of CRISPR And CRISPR-Associated (Cas) Genes by Type (2021-2026)10.1.2 Global Forecasted Revenue of CRISPR And CRISPR-Associated (Cas) Genes by Type (2021-2026)10.2 CRISPR And CRISPR-Associated (Cas) Genes Market Estimates and Projections by Application10.2.1 Global Forecasted Sales of CRISPR And CRISPR-Associated (Cas) Genes by Application (2021-2026)10.2.2 Global Forecasted Revenue of CRISPR And CRISPR-Associated (Cas) Genes by Application (2021-2026)10.3 CRISPR And CRISPR-Associated (Cas) Genes Market Estimates and Projections by Region10.3.1 Global Forecasted Sales of CRISPR And CRISPR-Associated (Cas) Genes by Region (2021-2026)10.3.2 Global Forecasted Revenue of CRISPR And CRISPR-Associated (Cas) Genes by Region (2021-2026)10.4 North America CRISPR And CRISPR-Associated (Cas) Genes Estimates and Projections (2021-2026)10.5 Europe CRISPR And CRISPR-Associated (Cas) Genes Estimates and Projections (2021-2026)10.6 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Estimates and Projections (2021-2026)10.7 Latin America CRISPR And CRISPR-Associated (Cas) Genes Estimates and Projections (2021-2026)10.8 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Estimates and Projections (2021-2026) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 DisclaimerAbout Us:QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See more here:

CRISPR And CRISPR-Associated (Cas) Genes Market Size, Share, Trends and Forecast 2026 by Major Players and Business Opportunities Caribou...

Researchers: Disease affecting kids could be in the genes – Newsday

Posted on by

The key to understanding and fighting the mysterious COVID-19-related inflammatory illness that is targeting children across the state could be in their genes.

The New York Genome Center is analyzingblood samples from the young patients with the hopes of finding genetic markers specific to the disease known as "pediatric multi-system inflammatory syndrome associated with COVID-19."

The state is investigating 102 cases of children who have the illness, which shows symptoms similar to Kawasaki disease or toxic shock syndrome. Three people, including an 18-year-old girl from Suffolk County, have died from the syndrome.

"This approach is widely used to study the genetic basis of all diseases, said Tom Maniatis, Evnin Family scientific director and chief executive officer of the New York Genome Center. We are trying to see if there are anygenetic clues to what might be causing this syndromein children.

If we can detect and understand thegenetic basis for predisposition, and how the immune system is affected in the disease, it might be possible to develop strategies for the clinical care of these children, he added.

Gov.Andrew M. Cuomo announced last week the state Department of Health was partnering with the Genome Center and The Rockefeller University to conduct a genome and RNA sequencing study of the illness, which hasbeen identified in 14 other states, including neighboring New Jersey and Connecticut, as well as five European countries.

Cuomo said Wednesday that60% of children with the illness have tested positive for COVID-19 and 40% had the antibody, meaning they may have been exposed to the coronavirus weeks before. Of those affected, 71% became seriously ill and were placed in intensive care units. He said 43% of those minors remain hospitalized and 19% had to be intubated.

According to a racial and ethnic breakdown of cases on thestate health department's website, 25% were white, 23% black, 20% other, 3% Asian and 31% unknown. In addition, 35% were Hispanic/Latino, 40% non Hispanic and 25% unknown.

Officials at Cohen Childrens Medical Center in New Hyde Park said they are seeing as many as two or three children a day with symptoms of the syndrome: fever and severe abdominal pain, rashes and red lips, eyes and tongue.

Experts believethe patients bodies might be having an extreme reaction to COVID-19, the disease caused by the novel coronavirus.

Whats so striking about this phenomena is that we all thought that most children were relatively safe, considering that they have the lowest mortality rate of any of the categories of COVID patients, Maniatis said.

A genome is an organisms complete set of DNA, including its genes, with all of the information needed to build and maintain that organism, according to the Bethesda, Maryland-based National Institutes of Health.

Researchers will look through the genome of patients in an effort to find DNA sequences that vary from the standard.

By comparing the childrens DNA sequence to the standard, we might be able to identify a variant that is not seen normally in most individuals, Maniatis said. And if you can show that it happens enough, you can begin to conclude that statistically its likely the DNA sequence change is associated with the disease."

The next step is RNA sequencing, which could provide insights into identification of altered immune pathways that are known to operate during virus infections.

Similar sequencing research conducted in the past led scientists to discover a gene mutation in people with blood cancer that impacted their immune system. A drug calledGleevec was developed to correct that mutation.

The Feinstein Institutes for Medical Research in Manhasset plans to participate in the study, said Dr. Peter Gregersen, professor of molecular medicine at Feinstein, the research arm of Northwell Health.

He said understanding the genetic variations of COVID-19 and the related illness thats attacking children is key to finding effective treatment.

We know age, sex and certain underlying conditions play a role, but genetic variations have something to do with this as well, Gregersen said. A lot of variations are unexplained. We know there is a huge variation, and some people dont get sick at all, while others have a devastating illness.

Maniatis said a vital part of the investigation is the collaboration with Jean-Laurent Casanova, head of the St. Giles Laboratory of Human Genetics of Infectious Diseases at The Rockefeller University.

He is one of the worlds experts in this field, and he established an international consortium directed toward understanding exceptional cases of clinical manifestations, Maniatis said. With Jean-Laurents participation, the search would extend from our efforts in New York and New Jersey to include researchers around the world and that will increase the statistical significance of any finding.

Lisa joined Newsday as a staff writer in 2019. She previously worked at amNewYork, the New York Daily News and the Asbury Park Press covering politics, government and general assignment.

Follow this link:

Researchers: Disease affecting kids could be in the genes - Newsday

Never Trumpers will host their own ‘Republican convention’ during the RNC – The Advocate

Posted on by

David Weigel, The Washington Post

Conservative critics of President Donald Trump will hold a convention of their own during the Republican National Convention, with plans to craft their own statement of principles and offer it to a post-Trump electorate.

"The Trump administration has failed, and that's provided us with an opportunity to offer an alternative vision," said Evan McMullin, who ran against Trump as an independent in 2016 and has been part of multiple anti-Trump efforts since then. "We'll be ready in the wake of what we see as a coming Trump defeat."

The Convention on Founding Principles is scheduled to run from Aug. 24 to Aug. 27 in Charlotte, the city hosting this year's RNC. The Republicans for a New President campaign, the chief organizer of the event, is planning an online component and a backup plan for a virtual convention if the RNC is canceled. Asked about the plans on Friday morning, the president's campaign brushed them off.

"These Trump haters are sad, pathetic, and irrelevant," said Trump campaign spokesman Tim Murtaugh. "President Trump has united Republicans and has unprecedented support within the party. He's also attracting non-Republicans and making huge inroads with blacks and Latinos. He will be reelected in November."

McMullin, who won 0.5% of the vote for his last-minute 2016 campaign against Trump, launched Stand Up Republic when that election was over. Republicans for a New President is that group's latest project, the most ambitious effort by anti-Trump conservatives who have run ads against Trump and held smaller conferences on what to do about the president.

The Convention on Founding Principles grew out of an event Trump critics held at the National Press Club this year, concurrent with the Conservative Political Action Conference. Organizers were pleasantly surprised when more than 300 people attended their counter-conference, prompting a move to a larger room.

The August event, said McMullin, would more closely resemble an actual political convention. There will be debates and voting on a statement of the attendees' principles, and a vote on whether they supported a particular candidate for president - presumptive Democratic nominee Joe Biden, or a "well-known third-party candidate." (Michigan Rep. Justin Amash, who is seeking the Libertarian Party's nomination for president, has been praised by many anti-Trump conservatives.)

"The convention will be centered around founding principles as its name indicates," McMullin said. "Candidates as well as current and former officeholders who honor those principles will be invited to speak, though that may or may not include presidential candidates."

This won't be the first unofficial gathering designed to contrast with a party's nominating convention. In 2016, some supporters of Sen. Bernie Sanders, I-Vt., organized a "People's Convention" in Philadelphia, where Hillary Clinton was accepting the Democratic nomination, and Green Party nominee Jill Stein stopped by.

In 2008 and 2012, after he unsuccessfully sought the Republican nomination, then-Rep. Ron Paul held all-day conferences near the sites of the party conventions. In 2000, campaign finance reformers organized a "Shadow Convention" near the DNC, lambasting the corporate donations that funded official party events.

"After Trump's expected loss to a cross-partisan coalition of voters in 2020, principled conservatives will continue to pursue a new direction for the party through a range of activities, intellectual, electoral and otherwise," McMullin said. 'Since 2016, principled conservatives have become more organized and more effective and this convention and campaign represent the next steps in the development of this strengthening movement."

Continued here:

Never Trumpers will host their own 'Republican convention' during the RNC - The Advocate

South Carolina Small Business Owner Responds To Toxic Allegations – FITSNews

Posted on by

Last month, our news outlet published an interview with a small business owner in downtown Columbia, South Carolina discussing the pressures the coronavirus pandemic had placed on her and her retail establishment. Over the weekend, we did another report on a small business in the Pee Dee region of the state one struggling with unfair enforcement of emergency edicts issued in the wake of the pandemic.

We believe it is important to tell these stories and share these perspectives.

So, how do we describe the story that has suddenly enveloped Katie Shields?

Unlike the others, thats for sure

Shields is the owner of Mylkbar a successful salon in Mount Pleasant, S.C. Earlier this month, she posted on her personal Instagram page of her interest in co-hosting a Keep America Great boat rally on May 23, 2020 (Memorial Day weekend).

While we are no longer in the business of defending U.S. president Donald Trump (owing to his many fiscal failures), we do not believe he is a racist. Nor have we ever believed that. Certainly, we do not believe supporting Trump is evidence of racism or that all (or even most) of his supporters are racist.

Nonetheless, many believe this unswervingly

Shortly after Shields posted on Instagram, another local business owner in the Charleston area accused her of being racist and greedy if you still support (Trump). Meanwhile, a Lowcountry radio host Tamika Gadsden excoriated Shields over her proposed boat rally, calling her reprehensible and referring to her as the face of white supremacy in the Charleston area.

In Charleston you learn, fairly quickly, that the face of White Supremacy resembles that of the boutique-owning, gatekeeping glitterati, she tweeted.

Seriously?

Yes

This news outlet reached out to Shields over the weekend hoping to get her thoughts on the situation. Luckily for our readers, she was kind enough to take the time to respond to our questions.

Below, in its entirety, is that conversation

Before we get into everything thats happened, tell us a little bit about yourself and your company. Where are you based? What does your company do? How have you and your employees been surviving COVID-19?

I founded Mylkbar three years ago after leaving the corporate world. We offer fume-free, natural nail services. Our flagship location in Mount Pleasant, S.C. closed for Covid-19 before governor Henry McMaster issued his executive order. Our team has followed all government regulations related to Covid-19.

Covid has been tough for everyone. We assumed the shutdown would be to flatten the curve and then we could return to work. Many small businesses have closed for good. My mother has bronchiectasis and Sjogrens syndrome, so I personally understand fear for the vulnerable and essential workers. Weighing these fears with long-term, grave consequences is critical. There is also a significant increase in child abuse, domestic violence, and suicides.

Those who actually know me can attest to my passion for the less fortunate and the organizations I care deeply about. Mylkbar recently gave a large amount to indigenous peoples displaced by wildfires in Australia and I have posted on my personal page about multiple nonprofits we give to regularly (even during quarantine). The only date night my husband I had during this shutdown was to safely serve food at a well-known homeless shelter downtown.

Before we get into your post and all the response it has generated, tell us a little bit about your politics.

I majored in Political Science and Economics and identify most closely with the Libertarian Party. Dr. Ron Paul is a retired Republican that I have always admired for his steadfast Constitutional views. I have also publicly applauded Jamal Holley (Democrat, New Jersey) for his outspoken views on medical freedom and some social programs. We are being conditioned to think that people who fight for freedom are selfish and this simply is not true.

So walk us through exactly what/ when/ where you posted on social media, and what your thought process was in posting it. We will get to the response in a moment, but first tell us about what you posted and why.

On Saturday, May 16 I posted an Instagram story on my personal and private Instagram page about a Trump Boat Parade on Memorial Day Weekend. Boat ramps in South Carolina have been open for weeks and social distancing is easily achieved on a boat. The whole state will be opened by Memorial Day Weekend and it is always a big boating weekend.

(Click to view)

(Via: Provided)

Pepi Rodriguez, owner of Lina Rosa Jewelry, was apparently very upset about this parade. Mylkbar was one of the first retailers to carry her line as the earrings are unique and beautiful! Pepi screen-shotted my post, made it her own, and encouraged people to boycott businesses owned by people who publicly support Trump characterizing them as racist, greedy, and shameful.

I reached out to Pepi with no response from her.

Pepi then decided to involve Tamika Gadsden, a local radio show host and activist. Gadsden took a photo of me and spread on all of her social channels that I was a white supremacist and reprehensible. They started referring to anyone who disagreed with their narrative as clanswomen and white supremacists. Some of my very Liberal-minded friends also came to my defense, but the damage was already done by Gadsden and Rodriguez.

Tamika Gadsden who made some pretty inflammatory remarks in response to what you posted. What do you have to say back to her?

I had never heard of Gadsden or her platform until a week ago. She took Rodriguezs post, and also created her own content, using my original post and various photos of me. She labeled me as a white supremacist and said I was organizing a nautical klan rally to honor the son of a klansman.

(Click to view)

(Via: Provided)

Gadsden and Rodriguez continued to associate the post with Mylkbar in an effort to not only destroy my character, but my business and family as well.

Gadsdens comments obviously drew a response from Kathryn Dennis of Southern Charm fame. What did you make of all that?

Many people were upset when they saw how I was getting cyber bullied. Kathryn Dennis got into a heated exchange with Tamika, which I did not know about until afterwards. I would never condone, or encourage, racist behavior or emojis and Kathryn has publicly apologized and I cant speak for her. I have personally never heard her make a racist remark.

Gadsden, and her followers, continue to post and screenshot the conversation with the offensive emoji and tag Mylkbar and my personal page, which is now deleted. It is not only defamation, but bad journalism because I was not involved.

Youve gotten some pretty scary threats in the aftermath of this situation. Can you tell us about some of those? Or better yet, show us?

Gadsden and Rodriguezs posts have caused a severe amount of emotional distress for my team, my family, and my children. We had to involve the police. Someone on Tamikas twitter encouraged extreme violence on her post about me and said why cant mass shootings happen at places like this. Tamika liked the comment, which is absolutely horrific. She has also encouraged people to hack my website.

(Click to view)

(Via: Provided)

So is there a double standard in our society? Obviously, the coverage of the sexual assault allegations against Joe Biden and the scandal involving Biden and other Obama-era officials spying on the Trump campaign have raised questions about the mainstream medias increasingly activist role in our country. How should we address this double standard?

I was attracted to tell my story on your website because you are independent. The media has encouraged this cancel culture of trying to limit free speech when it does not fit their agenda.

What sort of lessons do you take from all this? What would you want people to know about your experience? What would you tell others dealing with similar attacks?

Looking back, it is best to not engage. We live in a society where people feel comfortable having conversations behind a keyboard that they would never have in person. I regret some of the ways I responded to a couple clients who tried to shame me from re-opening Mylkbar when it was going to be legal to do so. I also am saddened that I have lost a few friends over differing views that occurred during quarantine.

I will not, however, apologize for supporting our sitting President. It does not make me racist. My views challenge people who want to control the narrative. If you are triggered by someone on social media, mute or skip their stories and move on with your day. I am confident in who I am and God knows my heart.

Continued here:

South Carolina Small Business Owner Responds To Toxic Allegations - FITSNews

Who will be Joe Biden’s co-president? – The Spectator USA

Posted on by

Joe Biden needs a co-president. Not just a running mate, not just a potential vice president, but someone who will be president-in-waiting should Biden win in November the month he turns 78.

The idea of Biden running for a second term in 2024 at the age of 81 is hard to take seriously. So far, this is something everybody knows but nobody is taking seriously enough.

The question of Bidens current mental acuity has become a campaign issue, but even Democrats who believe Biden is up to the job of being president in 2020 will have a tough time arguing that hed be fit to serve a second term.

In looking at the Democratic ticket this year, voters will in effect be asked to vote not just for a president but for a 2024 nominee as well.

Bidens campaign is staked on the idea that America wants to turn back the clock and return to the pre-Trump idea of normal. The polls suggest that theres plenty of appetite for this, and the older Americans who along with black voters secured the Democratic nomination for Biden might be especially open to reversing the flow of time.

Yet thats hopeless: the 2020s are set to begin with a radically new relationship between the US and China, the worlds strongest military and economic powers, along with what may be the worst domestic economy since the Great Depression.

The Republican party has been living in the future for a dozen years now: Ron Pauls populist libertarian revolt within the GOP in 2008, Sarah Palins place on John McCains presidential ticket that year, the Christian populist campaigns of Mike Huckabee and Rick Santorum in 08 and 12, and the Tea Party all signaled a move away from the normal politics of the 1990s.

Barack Obama was a half-step into the future for Democrats: a new face on most of the same old policies, including war in the Middle East and a Mitt Romney-spawned healthcare plan.

Then the Democrats nominated Hillary Clinton, who retreated into 90s nostalgia and lost to Donald Trump, a man who represented a truly dramatic break with what had gone before. Now Biden is the second backward-looking Democratic nominee in as many elections, and the question to be answered by his pick of running mate has to be: what vision does Bidens Democratic party have of the future if any?

Nancy Pelosi (already 80) and Chuck Schumer (70 in November), the leading Democrats in Congress, have failed to reproduce, ideologically speaking. Young Democrats are Bernie Democrats they were the voters who reliably supported him even as his campaign collapsed while Biden won primary after primary. A balanced ticket would call for a young Bernie as Bidens running mate. There isnt one available. Elizabeth Warrens name in Sanders-activist circles is about as popular as Jill Steins is on MSNBC. Warren turns 71 next month; shes hardly the person to rejuvenate a party desperate for plausible new leadership.

Alexandria Ocasio-Cortez is not eligible or qualified. The other contenders who are conventionally qualified dont have any special appeal to the Sanderistas, and dont imply a definite new direction for Democrats after Bidens placeholder administration.

But they can be ranked on other criteria, notably what they add to the tickets Electoral College prospects. Kamala Harris, it might be hoped, would help turn out black voters across the country, reinforcing Bidens already strong prospects in Pennsylvania. But thats not very plausible: Harriss presidential campaign was a dud and Biden has had no trouble turning out black voters on his own. California, Harriss state, is a world away from the industrial Midwestern and Mid-Atlantic states that Biden needs to win.

Minnesota senator Amy Klobuchar outpolled Harris in the Democratic contests and has a Midwestern political pedigree. She also has a reputation for being prickly and hot-tempered, traits that would not be assets in a vice president and presumptive 2024 nominee. On the campaign trail, she might seem like a lively contrast to Mike Pence Klobuchar usually seemed to be having fun during her presidential run, when she wasnt unable to conceal her irritation at being outsmarted by Pete Buttigieg. Pence is nobodys idea of fun, but he might also make her irritable in debate.

What does Klobuchar bring with her in terms of electoral votes? Minnesota only narrowly went to Clinton the last time around, but Biden needs to expand Clintons map if hes going to win, not lock it in place.

The smarter play for the Midwest might be Michigan governor Gretchen Whitmer, whose state went to Trump in 2016 by barely more than 0.2 percent of the vote. Whitmer bested Republican Bill Schuette by nearly 10 points in her states 2018 gubernatorial match-up. Biden has been leading in polls of Michigan, but with the possibility that one of the states congressmen, Justin Amash, will also be on the ballot in November as the Libertarian partys presidential nominee Biden might not want to risk a split in the anti-Trump vote causing him to lose the state. Whitmer would be insurance against that.

Gov. Whitmers response to COVID-19 has been especially heavy-handed, however. Polls in March showed the Michigan public backing her position. But how popular her lockdown politics will be in November is anyones guess. Does Biden want to place a bet?

Maybe President Trump will: it must cross his mind that he could blunt Bidens appeal to women by putting a woman on the Republican ticket in place of Pence. Borderline NeverTrump Republicans would love to see Nikki Haley on the ticket. Trumps base, which is by all indications hostile to lockdown politics, would be more energized by seeing South Dakota governor Kristi Noem as Trumps running mate. Yet Trump, unlike Biden, doesnt suffer from an enthusiasm problem with his own party only some 24 percent of Democrats surveyed by ABC News and the Washington Post in late March were very enthusiastic about Biden, the lowest figure in the history of the ABC/Post poll. 53 percent of Republicans in the same poll were highly enthusiastic about Trump.

The successful presidential contenders of the last 20 years have all used the VP slot to compensate for inexperience. George W. Bush, a virgin to Washington, added the experienced Dick Cheney to his ticket. Barack Obama, who hadnt yet finished his first term as a senator, chose the long-serving Biden as his running mate. And Trump picked Pence, whose credentials as a conventional conservative Christian Republican, governor, and former congressman were a balance for Trumps radically new and different political resume and persona. An incumbent president doesnt need anyone to lend him an imprimatur of experience, and Trumps popularity with the GOP base is such that no backlash from replacing Pence seems likely. Yet a Trump VP switch would be presented by the media as a sign of a campaign in freefall. And losing Pence might mean a marginal loss in Christian and stalwart Republican support that could outweigh any gains among women. Still, with word that Trump is looking to bring Corey Lewandowski back for his re-election campaign, anything is possible.

Biden doesnt need a running mate with experience. He needs someone who can plausibly represent the future of the Democratic party and who could be sworn in as president in January 2025 or earlier, if the countrys oldest president should die or become incapacitated in office. Biden has preemptively narrowed the search for his running mate and the Democrats 2024 nominee to women only. Was it wise to exclude half the population including such diverse young Democrats as Pete Buttigieg and Cory Booker from any consideration in this far-reaching decision right from the start? Biden is only thinking about November, but his voters will have to think about the November election four years from now as well, when Biden will turn 82. Do even the 24 percent of Democrats who are enthusiastic about Biden now imagine that hell be on the ballot in 2024? If not, what woman are they prepared to pre-elect today? She needs to have electoral credibility to help Biden here and now. But she also needs to have the focus and creativity to lead like Franklin Roosevelt or Harry Truman if this decade continues going the way its begun. And whomever the Democrats pick, even if victorious this year and in 2024, will have to face Republican populism for a long time. The Sanders wing of the party was confident it could do that. The Clinton-Biden, Schumer-Pelosi wing? Though it might yet win an election, its already losing the future.

View original post here:

Who will be Joe Biden's co-president? - The Spectator USA

An updated look at who is coming and going in the Big Ten for the 2020-21 season – Inside the Hall

Posted on by

With player movement continuing around the country, its time for an updated look at who is coming and going in the Big Ten for the 2020-21 season.

(Note: This is the third post in a series that will be updated multiple times in the coming months. In most instances, only scholarship players are included. If we missed anything, please email corrections to[emailprotected] or post in the comments.)

Illinois

Returning: Trent Frazier, Giorgi Bezhanishvili, DaMonte Williams, Austin Hutcherson, Jermaine Hamlin, Benjamin Bosmans-Verdonk, Jacob GrandisonNBA draft early entrants: Kofi Cockburn (testing), Ayo Dosunmu (testing, likely staying in)Arriving: Andre Curbelo (247Composite top 100), Adam Miller (247Composite top 100), Coleman HawkinsDeparting: Alan Griffin (transfer), Kipper Nichols, Tevian Jones (transfer), Andres Feliz

Notes: With the NCAA opting to extend the deadline for players to withdraw from the NBA draft and retain their eligibility, Illinois will have to wait to solidify its roster for next season. Dosunmu is expected to remain in the draft, but the Cockburn decision looms large for the Illini.

Indiana

Returning: Al Durham Jr., Joey Brunk, Race Thompson, Jerome Hunter, Rob Phinisee, Trayce Jackson-Davis, Armaan FranklinNBA draft early entrants: Justin Smith (testing)Arriving: Anthony Leal (247Composite top 100), Trey Galloway, Jordan Geronimo, Khristian Lander (247Composite top 100)Departing: Devonte Green, DeRon Davis, Damezi Anderson (transfer)

Notes: Since our last update, Smith put his name into the NBA draft pool and Lander officially moved into the 2020 recruiting class.

Iowa

Returning: Jordan Bohannon, Joe Wieskamp, Jack Nunge, CJ Fredrick, Connor McCaffery, Pat McCaffery, Joe ToussaintNBA draft early entrants: Luka Garza (testing)Arriving: Ahron Ulis, Tony Perkins, Josh Ogundele, Keegan Murray, Kris MurrayDeparting: Ryan Kreiner, Cordell Pemsl (transfer)

Notes: The Hawkeyes received good news last week as Bohannon was granted a fifth year of eligibility.

Maryland

Returning: Eric Ayala, Aaron Wiggins, Serrel Smith Jr., Darryl Morsell, Donta Scott, Chol MarialNBA draft early entrants: Jalen Smith (staying in)Arriving: Jairus Hamilton (transfer from Boston College), Marcus Dockery, Aquan Smart, Galin Smith (graduate transfer from Alabama)Departing: Anthony Cowan, Ricky Lindo Jr. (transfer), Joshua Tomaic (transfer)

Notes: The Terps bolstered their frontcourt with the addition of Smith, who averaged 3.1 points and 2.5 rebounds last season for Alabama.

Michigan

Returning: Austin Davis, Adrien Nunez, Brandon Johns, Eli Brooks, Franz WagnerNBA draft early entrants: Isaiah Livers (testing)Arriving: Mike Smith (graduate transfer from Columbia), Zeb Jackson (247Composite top 100), Hunter Dickinson (247Composite top 100), Terrance Williams (247Composite top 100), Jace Howard, Nojel Eastern (transfer from Purdue)Departing: Zavier Simpson, Jon Teske, David DeJulius (transfer), Colin Castleton (transfer), Cole Bajema (transfer)

Notes: Its been an eventful offseason in Ann Arbor. Since our last update, Bajema transferred to Washington and Eastern transferred to Michigan. Will Eastern get a waiver to play next season?

Michigan State

Returning: Foster Loyer, Gabe Brown, Thomas Kithier, Marcus Bingham Jr., Malik Hall, Rocket Watts, Julius Marble, Joey HauserNBA draft early entrants: Xavier Tillman (testing, likely staying in), Aaron Henry (testing)Arriving: Mady Sissoko (247Composite top 100), AJ Hoggard (247Composite top 100)Departing: Cassius Winston, Joshua Langford (could apply for fifth year of eligibility), Kyle Ahrens

Notes: One roster issue still to be decided in East Lansing: Will Langford attempt to return next season?

Minnesota

Returning: Eric Curry, Gabe Kalscheur, Jarvis Omersa, Tre Williams, Sam Freeman, Isaiah IhnenNBA draft early entrants: Daniel Oturu (staying in), Marcus Carr (testing)Arriving: Brandon Johnson (graduate transfer from Western Michigan), Liam Robbins (transfer from Drake), Jamal Mashburn Jr. (247Composite top 100), Martice MitchellDeparting: Payton Willis (transfer), Michael Hurt, Alihan Demir, Bryan Greenlee (transfer)

Notes: Since our last update, Greenlee put his name into the transfer portal.

Nebraska

Returning: Thorir Thorbjarnarson, Akol Arop, Shamiel Stevenson, Derrick Walker, Yvan Ouedraogo, Dalano BantonNBA draft early entrants: NoneArriving: Kobe King (transfer from Wisconsin), Trey McGowens (transfer from Pittsburgh), Kobe Webster (graduate transfer from Western Illinois), Teddy Allen, Lat Mayen, Trevor Lakes (transfer from Indianapolis, will sit out), Eduardo AndreDeparting: Cam Mack (transfer), Dachon Burke (transfer), Jervay Green (transfer), Haanif Cheatham, Matej Kavas, Kevin Cross (transfer), Charlie Easley (transfer)

Notes: Nebraskas offseason has been eventful. Since our last update, the Huskers added Andre, a top 200 recruit and Lakes, a DII player who will sit out next season.

Northwestern

Returning: Ryan Greer, Miller Kopp, Pete Nance, Anthony Gaines, Ryan Young, Robbie Beran, Boo Buie, Chase AudigeNBA draft early entrants: NoneArriving: Ty Berry, Matt NicholsonDeparting: A.J. Turner, Pat Spencer, Jared Jones (transfer)

Notes: Theres been no movement this offseason for Northwestern other than the Jones transfer.

Ohio State

Returning: Musa Jallow, Duane Washington Jr., Justin Ahrens, Kyle Young, EJ Liddell, Ibrahima Diallo, Justice SeuingNBA draft early entrants: Kaleb Wesson (testing, likely staying in), CJ Walker (testing)Arriving: Jimmy Sotos (transfer from Bucknell), Seth Towns (graduate transfer from Harvard), Abel Porter (graduate transfer from Utah State), Eugene Brown III, Zed KeyDeparting: Andre Wesson, DJ Carton (transfer), Alonzo Gaffney (transfer), Luther Muhammad (transfer)

Notes: It could be a retooling season in Columbus if Wesson keeps his name in the NBA draft.

Penn State

Returning: Myles Dread, Izaiah Brockington, Myreon Jones, John Harrar, Jamari Wheeler, Trent Buttrick, Seth Lundy, Patrick KellyNBA draft early entrants: NoneArriving: Sam Sessoms (transfer from Binghamton), Dallion Johnson, DJ Gordon, Valdir Manuel, Caleb DorseyDeparting: Lamar Stevens, Mike Watkins, Curtis Jones Jr.

Notes: After being a lock to make the NCAA tournament this season, Penn State will face an uphill battle next season without Stevens.

Purdue

Returning: Aaron Wheeler, Eric Hunter, Trevion Williams, Emmanuel Dowuona, Sasha Stefanovic, Brandon Newman, Mason Gillis, Isaiah ThompsonNBA draft early entrants: NoneArriving: Jaden Ivey (247Composite top 100), Ethan Morton (247Composite top 100), Zach EdeyDeparting: Matt Haarms (transfer), Evan Boudreaux, Jaahad Proctor, Nojel Eastern (transfer)

Notes: Since our last update, Eastern entered the transfer portal and days later, committed to Michigan.

Rutgers

Returning: Geo Baker, Myles Johnson, Mamadou Doucoure, Montez Mathis, Ron Harper Jr., Caleb McConnell, Jacob Young, Paul MulcahyNBA draft early entrants: NoneArriving: Cliff Omoruyi (247Composite top 100), Mawot Mag, Dean Reiber, Oskar PalmquistDeparting: Akwasi Yeboah, Shaq Carter, Peter Kiss (transfer)

Notes: Since our last update, Kiss transferred to Bryant.

Wisconsin

Returning: DMitrik Trice, Micah Potter, Aleem Ford, Brad Davison, Nate Reuvers, Trevor Anderson, Joe Hedstrom, Tyler WahlNBA draft early entrants: NoneArriving: Ben Carlson (247Composite top 100), Johnny Davis, Lorne Bowman, Steven Crowl, Jordan DavisDeparting: Brevin Pritzl, Kobe King (transfer)

Notes: The Badgers will likely enter the 2020-21 season as the favorite to win the conference.

Filed to: 2020-2021 Big Ten preview

Go here to see the original:

An updated look at who is coming and going in the Big Ten for the 2020-21 season - Inside the Hall

The Psychedelic Renaissance with the former VP of content at High Times (Brains Byte Back podcast) – The Sociable

Posted on by

Our Brains Byte Back podcast co-host, Mags Tanev, kicks off her new seriesThe New Era of Psychedelics,exploring scientific research, therapies, and the potential benefits of psychedelic compounds and plant medicines in our societies.

In this first installment, Tanev interviews Jackee Stang, the founder of Delic Corp,the first-ever psychedelics corporation that specializes in education, content, and events about psychedelic substances.

In addition to this, she is also the former VP of content and programming at High Times.

Listen to this podcast onSpotify,Anchor,Apple Podcasts,Breaker,Google Podcasts,Stitcher,Overcast,Listen Notes, andRadio Public.

In this episode, they discuss Jackees journey with psychedelics, her motivation to start Delic Corp, and the challenges she has faced within the psychedelic community.

Magic mushrooms as a cyberdelic technology for hacking consciousness

How to biohack your body (Part 1) on Brains Byte Back

Biotech startup wants to make new short-acting psychedelic drugs more scalable & accessible

Go here to read the rest:

The Psychedelic Renaissance with the former VP of content at High Times (Brains Byte Back podcast) - The Sociable

Have a Good Trip Demystifies Psychedelics – The New Republic

Posted on by

Irony, of course, is the main line to Have A Good Trips target audience: nostalgic Gen Xers and elder millennials whose interest in high-power hallucinogens has likely been piqued by the so-called psychedelic renaissance. There is, I suspect, a certain level of knowing irony in other quarters of the psychedelic revival, be it in the popularity of neo-psychedelic rock bands like Tame Impala or King Gizzard and the Lizard Wizard (whose names alone suggest forked tongues firmly in cheek) or the elevation of pilled Grateful Dead tie-dye tour shirts to pricy, haute couture attire. Modern psychedelic explorers engage with the culture but avoid the effusions of earnestness that made the fizzled cultural revolutions of the boomer generation feel so embarrassing. The third eye is awakened and already rolling.

But can you really remove sincerity from the psychedelic experience, which has long been vaunted for its ability to facilitate beautiful insights about the power of capital-l Love; insights that may scan like mush when the drugs effects have faded but feel, in that exalted moment, absolutely real? And more to the point, should you want to? After all, one of the characteristics of the psychedelic trip is its capacity to obliterate what Pollan calls the pitiless glare of irony. Its that feeling of openness or a universal oneness that reoccurs in psychedelic literature, cinema, and even the woolly anecdotes of friends. Irony has become a de facto cultural defense mechanism and is rendered vulnerable by drugs renowned for opening (or totally shattering) our psychic defenses.

Irony is perhaps useful in tempering a bit of the cultural bitterness associated with the movements of psychedelias last major saturation period: the 1960s. Psychedelic drugs fueled the artistic and political upheavals of America in the Age of Aquarius, which collapsed under the bummer-trip heaviness of Altamont, the Manson murders, and the national trauma of the Vietnam War. As author Tom ONeill puts it in Chaos, his recent history that rethinks the era, The decades subversive spirit had come on with too much fervor. Some reckoning was bound to come, or so it seemed in retrospect; the latent violence couldnt contain itself forever. This cultural comedown is often framed, in distinctly druggy terms, as a form of punishment for the ecstasies that preceded itlike a long, blue Monday of the American spirit.

The psychedelic revivals ironic edge cuts some of this, allowing the curious-minded to savor the hallucinatory fruits of the era without getting swept up in its politics, which, as we all know, were tainted and stupid and hopelessly nave. (New reporting about the period, including ONeills book, strongly suggests that this sense of hopelessness and navet was a deliberate strategy by the powers-that-be to neutralize the energized leftist movements of the 1960s, but thats another discussion altogether.) A veil of wizened, weary cynicism permits engagement in psychedelia without having to feel all that engaged with its history or its deeper, metaphysical implications.

More here:

Have a Good Trip Demystifies Psychedelics - The New Republic

Psychedelic experiences disrupt routine thinking and so has the coronavirus pandemic – The Conversation CA

Posted on by

The COVID-19 pandemic has resulted in the widespread disruption of our usual routines. The ambiguity of when it will end, how things will unfold and what will happen in the future has resulted in a collective liminal state, a kind of a waiting area on the threshold of change.

COVID-19 has undermined our usual expectations and assumptions. Evidence from my work on how our brains react to psychedelics tell me the transient anxiety which occurs when expectations collapse may yield benefits. To gain the benefits, we must be intentional in the viewing of this era as a transformational opportunity.

I have looked at how medium-to-high doses of psychedelics can help reset the brain, shaking it out of old patterns. I wonder if our current state of uncertainty could have similar impacts on the brain a metaphorical psychedelic dose for new insights, values clarification and a collective reset.

A recent study shows experiences with psychedelics such as psilocybin (also known as magic mushrooms) can have disruptive impacts on our brains. Neuroimaging of the brain on psychedelics have revealed a state of chaos, or entropy and a loss of synchronization of brain waves.

Entropy is a measure of uncertainty and randomness or disorder. British neuroscientist Karl Friston defines entropy as a measure of uncertainty, the average surprise. Low entropy means, on average, that outcomes are relatively predictable.

In Fristons view, the brain is a prediction machine. We construct the future from the past. We make predictive inferences (conscious and unconscious) to conserve energy and simplify the interpretation of a continuous input of stimuli.

We gain mastery, but at the expense of novelty.

Poor mental health often revolves around excessive rumination and repetition. Rumination is rigid, repetitive and negative thinking characterized by low entropy.

In 1949, McGill University psychologist Donald Hebb predicted much of what modern neuroscience would go on to prove with neuroimaging technologies. Hebbs postulate that the neurons that fire together, wire together provides a summary of the way synaptic pathways bond and are reinforced by repetition.

This repetition and rumination robs the mind of flexibility, especially when attached to memories with heightened (positive or negative) emotional resonance. Repetition-habituated brains marinate in a soup of low novelty and lack of surprise, forecasting tomorrow to be much the same as today.

Psychedelics disrupt our repetitive or ruminative ways of thinking and rewire brain communication patterns. The result is often an altered state of consciousness marked by transient confusion, followed by a high probability of novel, meaningful and possibly even mystical experiences.

When the rigid, top-down control of the ego is loosened, the anarchy of the creative unconscious blooms.

Our research group at Queens University recently completed a review of existing studies on psilocybin-assisted therapy. From over 2,000 records, we found nine completed clinical trials with a total of 169 participants.

Overall, the trials showed that most subjects safely tolerated these interventions and showed improved mental health. However, some experienced transient distress and post-treatment headaches. The trend suggests positive outcomes in various conditions such as obsessive-compulsive disorder, addiction, depression, psychological distress associated with life-threatening cancers and demoralization among long-term AIDS survivors.

In short, although psychedelics can be accompanied by known adverse experiences, trials seem to indicate that psilocybin is relatively safe (with the right supports and in a supportive setting) and has a marked ability to interrupt psychopathologies.

To ensure safety and support, the majority of psilocybin trials used the PSI model (preparation, session, integration) with multiple moderate-to-high-doses sessions happening in the company of trained therapists.

Participants report experiences of transient anxiety, distress and confusion, states of joy, interconnectedness, catharsis, forgiveness and wisdom experiences. In contrast to talk therapy, psychedelic sessions are experiential, meaning that we experience changed ways of both seeing and being in the world.

Mystical experiences have been reported both by clinical trial subjects and by recreational psilocybin users. Mysticism can be thought of as an experience of absorption, a dissolution of separateness and a sense of deep connection. Absorption is the opposite of rumination.

Rumination carries you away on an eddy of self-referential and self-containing thoughts, while when experiencing absorption, you leave behind your narrow sense of self, experiencing something greater that is both inside and outside of you.

The psychedelic experience is a classic heros journey. The hero leaves the comforts of home, faces disruption and challenges to their previous way of thinking and being, has profound and transformative experiences, and returns a changed person.

Leaving predictability and entering into uncertainty is a threshold to transformation.

In one study, psilocybin trial subjects reported feeling more deeply connected, open and relational as a result of their entropic, and often difficult, psychedelic experiences. In another study, they have been found to hold less authoritarian political views and be more in touch with nature.

Participants in collective psychedelic rituals commonly experience feelings of deep bond, kinship and even telepathy with other participants. I believe we may be in a similar moment during COVID-19.

COVID-19 has disrupted the normative habits of society. It has forced the economic machine to pause. It has forced many to reevaluate practices and priorities. In some cases, I believe it is dissolving our normal sense of human separateness (even though we are physically distanced).

Perhaps, like the liminal psychedelic state, the uncertainty in which we find ourselves in this moment will lead to more visions of what can be.

The future does not have to remain in the past.

Those of us with the luxury of space and time have an opportunity to reset, unbind our minds, quit repeating old patterns, experience anew what life can hold and to do better.

Continued here:

Psychedelic experiences disrupt routine thinking and so has the coronavirus pandemic - The Conversation CA

Psilocybin: An Effective Treatment for Weight Loss and Food Craving? – Yahoo Finance

Posted on by

Houston, Texas--(Newsfile Corp. - May 19, 2020) - Psychedelics may soon alter the way we address mental and health issues.

That may be especially true when it comes to treating obesity, which has been recognized by the World Health Organization as a global epidemic, with at least 2.8 million people dying each year as a result. In addition, according to the World Health Organization, more than 1.9 billion adults, 18 years and older, are overweight. Of these over 650 million are obese.

Those are startling statistics. However, there may be a psychedelic solution.

Psilocybin Could Help Solve that Global Obesity Epidemic

One of the key psychedelics that may assist with treating obesity are psilocybin mushrooms, which can also assist with issues such as PTSD, depression, anxiety, obsessive compulsive disorder, and even chronic pain.

Even Johns Hopkins Medicine's Center for Psychedelic and Consciousness Research, for example, is focusing on psychedelics, including psilocybin for the treatment of eating disorders.

Companies like Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) subsidiary NeonMind Biosciences Inc. are also nearing studies to confirm that is an effective treatment for weight loss and food craving. The goal of this study is to use preclinical models to confirm that psilocybin is an effective treatment for weight loss and food craving.

NeonMind will use models that have been widely adopted by the pharmaceutical industry to identify compounds with therapeutic efficacy. It plans to use results from this study as part of the requirements for a Health Canada clinical trial application to demonstrate potential efficacy and safety for novel compounds.

NeoMind Biosciences Ltd. Files U.S. for Patent

NeonMind also filed a U.S. provisional patent application to protect intellectual property relating to the use of compounds found in psychedelic mushrooms to lose weight.

NeonMind's pending patent includes the use of psilocybin to help with weight loss, reduce food cravings, counter compulsive eating, improve quality of diet, increase metabolism, treat diabetes, regulate blood glucose levels, and help reduce susceptibility to cardiovascular disease, high blood pressure, and other issues associated with diabetes.

The company hopes to tap into multi-billion-dollar market opportunities, including the $245 billion weight loss and management market, $64 billion cardiovascular disease treatments, the $156 billion depression market, and the $87 billion diabetes treatment market.

For more information, visit the company's website at https://yieldgrowth.com.

About MarijuanaStox

MarijuanaStox.com is a leading web destination for all cannabis related companies. Investors can also find current marijuana-related quality financial, medical, legal and social news. MarijuanaStox.com is a media agency in North America dedicated to the cannabis industry, helping companies that operate in the space to attract quality investors, working capital and real publicity. Since 2005, we have had public companies in the US and Canada have rely on us to grow and succeed.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with http://www.MarijuanaStox.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with http://www.MarijuanaStox.com, is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of MarijuanaStox.com) and The Yield Growth Corp, Winning Media has been paid four thousand dollars for advertising and marketing services for The Yield Growth Corp. We own ZERO shares of The Yield Growth Corp. Please click here for full disclaimer.

Contact Information:2818047972ty@marijuanastox.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/56108

More here:

Psilocybin: An Effective Treatment for Weight Loss and Food Craving? - Yahoo Finance

This Trippy Oregon Theme Park Is Like A Psychedelic Disneyland – Thrillist

Posted on by

My most vivid childhood memories of Enchanted Forest are of Storybrook Lane, the parks original attraction. It takes you down a leafy path full of storybook oddities: fairytale figurines that appear poised to come alive; a jumbo Humpty Dumpty grinning atop a wall; a dark, dank Alice In Wonderland tunnel carved out of a faux tree stump; and an anthropomorphic caterpillar perched on a larger-than-life neon pink mushroom.

While my perspective hasnt changed much in the 22 years since, I now have the precise words to describe the place: trippy as shit.

In theme and physical size, this peculiar amusement park in Turner, Oregon -- which turns 50 this year -- caters to small children. But over the years, it's also become a low-key psychedelic playground for grownups thanks to a combination of social media, nostalgia, legal cannabis, and hallucinogens. In a state that fully embraces weirdness, Enchanted Forest is a jewel perfectly at home among the trees just off the highway.

For Sara Rudolph, Enchanted Forest is a reversion to childhood, one thats typically facilitated by psychedelic mushrooms.Rudolph has been going to the park since she was three. She remembers being thrilled and a little alarmed by the folksy handmade attractions -- among them a giant slide you enter through a witch's gnarled maw and a rickety haunted house.

Her last visit to the park was last year, at the age of 43. She says she hasnt gone to Enchanted Forest entirely sober since she was about 16, and as an adult, 'shrooms help her recreate moments of adolescent wonder.

Recommended

Travel

Thrillist's Best (and the Rest): Traveling With a Partner vs. Traveling in a Big Group

"There are all these little alcoves with puppets that definitely look like they come alive at night."

Its an immersive experience, something that we are very there for as children, but less so as adults," she says. "If you're high, you have more levels of that [childhood] experience. It's not just visual: You're actually more involved and more affected by the tactile nature of it.

Enchanted Forest can be trippy in a fun way -- or terrifying, depending on how high you are.

Its sort of homemade, which makes it extra creepy, Rudolph says. It's definitely not Disneyland. You're not sitting safe in a little cart. You're walking through it and it's kind of unpredictable and there are '70s-style, weird, lurid colors.

Enchanted Forest dates back to 1964, when Roger Tofte began building it on a 20-acre forested hill outside of Salem, according to the website. The park officially opened in 1971, with a piece of butcher paper that read OPEN alerting people to its existence.

Tofte, an artist and tinkerer who is now 90 years old, wanted to give kids in the sleepy city of Salem (the state capital, about an hour south of Portland) something to do. He built the park by hand with his wife, Mavis, and four kids.

Susan Vaslev, Toftes oldest daughter who now helps run Enchanted Forest, says there have been a couple of dips in attendance throughout the years that threatened the parks survival. The first was in the 1970s, when oil crises led to nationwide gas shortages, and the second was after 9/11. Currently, attendance is at a standstill as nonessential businesses are shuttered. Its 50th anniversary celebration is a big question mark.

Our biggest business is repeat visitors, Vaslev says. We're very thankful to them because that's what keeps us going.

The parks official Instagram -- which features photos of a smiling, wizened Tofte still repairing and shoring up the park by hand -- has over 10,000 followers. On it, youll find collections of fan art, vintage photos, and promos from the time the park was the subject of Travel Channels Ghost Adventures (the crew believed it was haunted). Threads on Twitter and Reddit, though, highlight the more underground aspects of the park.

Venture deep enough down the internet rabbit hole and youll find fan reviews of the Music From Enchanted Forest album, a collection of storybook-synth tunes composed by Vaslev that play on loop throughout the park. Search Reddit and youll find an Ask Me Anything thread with somebody claiming to be an employee in 2018.

What's the strangest thing you've caught visitors doing who didn't know you were watching? a user called IronicallyZen asked.

Definitely pot smoking! the employee responded. Young people think they could come in and sneak a smoke in the dwarf caves or bathrooms, but employees roam around constantly and they are for sure not getting away with it.

I couldnt imagine not going high.

Douglas Elkins, co-owner of Salems OG Collective Dispensary, says cannabis isn't necessarily the drug of choice for Enchanted Forest Visitors, but hes certainly heard of people doing acid and 'shrooms and going to Enchanted Forest.

Vaslev, however, vehemently denies the parks reputation as a destination for psychedelic enthusiasts.Rumors are rumors and not what we see in the park. We're very family-oriented, Vaslev says. If people come intoxicated, on alcohol or drugs or cannabis, we will ask them to leave or call the police.

I couldnt imagine not going high, says Crystal Contreras. It would seem kind of sad.

Contreras, 37, learned about Enchanted Forest after moving to Oregon as an adult.I heard that [taking psychedelics before going to the park] was a thing people do from a friend who grew up here, Contreras says.

Her inaugural visit was with a group of friends, who all took mushrooms. Because it was a sweltering summer day, Contreras opted to be the relatively sober friend and go very, very high on cannabis instead. She learned it was beneficial to have a high tolerance for spookiness.

Theres definitely a contrast between it being cute and fun and really creepy, Contreras says. It has a weird acid-trip aesthetic. There are all these little alcoves with puppets depicting scenes from fairy tales that definitely look like they come alive at night.

At one point, going through one of the little houses, Contreras says she, got a feeling that if I let my friends out of my sight they would disappear forever and Id never find them.

Contreras and Rudolph have advice for adults who decide to microdose before their trip to Enchanted Forest. The best ride, they both agree, is the new Challenge of Mondor, a target-shooting game that winds slowly through a dark tavern.

You get to chill out and shoot targets with a laser gun, who wouldnt like that? Contreras says.

Rudolph also recommends the Fantasy Fountains Water-Light Show -- a beautiful, dazzling water and light show that has 359 water jets, according to the parks website.

But she warns against the Ice Mountain Bobsled Roller Coaster, a Matterhorn knock-off that was the parks first ride.They put you in a little plastic capsule and it is incredibly claustrophobic, Rudolph says. If you're over five foot four, especially on drugs, maybe skip out.

Read more here:

This Trippy Oregon Theme Park Is Like A Psychedelic Disneyland - Thrillist

REPEAT – Champignon Sponsors Non-profit Coalition, TheraPsil – Medical Psilocybin Access Project for Palliative Cancer Patients and Health…

Posted on by

VANCOUVER, British Columbia, May 19, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (Champignon or the Company) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences Company with an emphasis on ketamine and psychedelic medicine, is pleased to sponsor TheraPsil, a BC-based non-profit coalition of healthcare professionals, policy-makers and community leaders (the TheraPsil Coalition) seeking legal access to psilocybin for British Columbians with a palliative diagnosis and psychological distress.

Operating at highest standards of clinical competence and ethical integrity, the TheraPsil coalition is starting in 2020 with seeking legal access to psilocybin for British Columbians with a palliative diagnosis and psychological distress.

Based in Victoria, British Columbia and established in 2019, TheraPsil is focused on:

Were really happy to have this support to get the ball rolling on this project to help palliative Canadians. We are dedicated to giving those at end-of-life the treatment options they deserve - and that includes psilocybin. We believe that as a non-profit, and with the right support, we can get these patients their right to treatment with psilocybin in a timely manner, Dr. Bruce Tobin, founder of TheraPsil.

Through our sponsorship, the Champignon team and board are extremely proud to begin collaborating alongside TheraPsil, helping patients in palliative care access new and effective therapies, said Pat McCutcheon, Director, Champignon. Together we will work to provide countless Canadians facing a palliative cancer diagnosis, along with their families, who also face severe psychological distress, with the treatment options, compassion and hope they deserve.

For information about the TheraPsils medical team and program, visit http://www.therapsil.ca.

About Champignon Brands Inc.

Champignon Brands (SHRM.CN) is focused on the formulation and manufacturing of novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutraceutical and psychedelic medicine while being supported by a leading psychedelics medicines clinic platform. The Company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami's Miller School of Medicine, the Company is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the Companys website at: https://champignonbrands.com/.

ON BEHALF OF THE BOARD OF DIRECTORS

Dr. Roger McIntyreChief Executive Officer T: +1(613) 967-9655E:info@champignonbrands.com

FOR INVESTOR INQUIRIES:

Tyler TroupCircadian GroupE:SHRM@champignonbrands.com

FOR CHAMPIGNON BRANDS FRENCH INQUIRIES:

Remy ScalabriniMaricom Inc.E: rs@maricom.ca T: (888) 585-MARI

The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Companys control. There are no assurances that the business plans for Champignon Brands described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Companys filings with Canadian securities regulators, which are available at http://www.sedar.com.

Story continues

See more here:

REPEAT - Champignon Sponsors Non-profit Coalition, TheraPsil - Medical Psilocybin Access Project for Palliative Cancer Patients and Health...

Novamind and Buzz Capital Announce Qualifying Transaction TSX Venture Exchange:BUZ-P – GlobeNewswire

Posted on by

Not for distribution to U.S. Newswire Services or for dissemination in theUnited States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.

TORONTO, May 18, 2020 (GLOBE NEWSWIRE) -- Buzz Capital Inc. (TSXV: BUZ.P) ("Buzz Capital" or the "Corporation"), a capital pool company listed on the TSX Venture Exchange (the "Exchange"), is pleased to announce that it has signed a letter of intent datedMay 8, 2020 (the "Letter of Intent") with Novamind Ventures Inc., an Ontario corporation, ("Novamind) to complete a business combination by way of a transaction that will constitute a reverse takeover of Buzz Capital by Novamind. The proposed transaction is intended to constitute an arms length qualifying transaction (the "Qualifying Transaction") for Buzz Capital, as defined in Policy 2.4 of the Exchange. Upon completion of the Qualifying Transaction and the Financing (as defined and described below), it is expected that Buzz Capital (following the Qualifying Transaction, the Resulting Issuer) will be a Tier 2 Industrial Issuer, subject to Exchange approval.

Description of Novamind

Novamind invests in the infrastructure that drives the worlds leading psychedelic clinics and retreats. Novamind was founded in May 2019 in Toronto, Canada.

Ongoing clinical trials approved by the U.S. Food and Drug Administration (FDA) are currently evaluating the safety and efficacy of MDMA-assisted psychotherapy (to treat PTSD) and psilocybin-assisted psychotherapy (to treat depression), and if approved, will require specialized infrastructure to facilitate patient treatment. Novamind seeks to accelerate research and innovation in psychedelic medicine by investing in the people, science and technology required for a regulated psychedelics industry.

Until such time that the FDA approves new psychedelic medicines, Novamind invests and operates exclusively in those jurisdictions with established legal regulations for the use of psychedelics. With this as a prerequisite, Novamind was an early mover in 2019 and made two strategic investments in industry-leading psychedelic retreats and clinics:

Novaminds investment in Synthesis and its acquisition (pending) of Cedar Psychiatry provides Novamind with access to proprietary resources including psychedelic-assisted psychotherapy protocols, industry-leading data, patient screening tools, leading facilitators and scientific advisors. Utilizing these best practices and partnering with leading practitioners in the psychedelic space, Novamind is building a network of clinics and retreats offering people access to safe, legal psychedelic experiences while advancing research for psychedelic medicine.

Additional information on Novamind will be provided in the filing statement to be filed pursuant to the Qualifying Transaction.

The Qualifying Transaction

The Letter of Intent contemplates that the Qualifying Transaction will be undertaken by way of a three-corner amalgamation, pursuant to which Novamind will amalgamate (the "Amalgamation") with a newly formed subsidiary of Buzz Capital and, as such, approval of the Novamind shareholders (Novamind Shareholders) will be required. Upon completion of the Amalgamation, the corporation formed by the amalgamation of Novamind and the newly-formed subsidiary of Buzz Capital will be a wholly-owned subsidiary of Buzz Capital.

Prior to the Amalgamation, Buzz Capital will effect a consolidation (the Buzz Consolidation) and Novamind will similarly effect a consolidation (the Novamind Consolidation; together with the Buzz Consolidation, the Consolidations) of, respectively, the issued and outstanding common shares of Buzz Capital (the Buzz Shares) and Novamind (the Novamind Shares). Under the Buzz Consolidation, the Buzz Shares will be consolidated on a basis that results in the holders of Buzz Shares (Buzz Shareholders) holding post-Buzz Consolidation Buzz Shares (Buzz Consolidated Shares) having a value of $1,700,000, provided that Buzz Capital has net cash of minimum $500,000 at closing. Assuming a net cash position of a minimum of $500,000, this would result in the Buzz Shares being consolidated on a 1:1.9788 basis, resulting in approximately 4,250,000 Buzz Consolidated Shares being outstanding. Under the Novamind Consolidation, the outstanding Novamind Shares will be consolidated on a 1:4 basis, resulting in Novamind Shareholders holding approximately 19,018,750 post-Novamind Consolidation Novamind Shares (Novamind Consolidated Shares). The number and exercise prices of the outstanding convertible securities of Buzz Capital (Buzz Convertible Securities) and Novamind (Novamind Convertible Securities; together with the Buzz Convertible Securities, the Convertible Securities) will be adjusted in accordance with their terms as a result of, respectively, the Buzz Consolidation and Novamind Consolidation.

Following the Consolidations and pursuant to the Amalgamation, the holders of Novamind Consolidated Shares immediately prior to the completion of the Amalgamation will each receive, for every one (1) Novamind Consolidated Share held immediately prior to the completion of the Amalgamation, one (1) Buzz Consolidated Share (the Exchange Ratio). Outstanding Novamind Convertible Securities will either automatically adjust in accordance with the terms thereof such that following the completion of the Amalgamation, the holders thereof shall acquire Buzz Consolidated Shares in lieu of Novamind Consolidated Shares or will be replaced with equivalent convertible securities of Buzz entitling the holders thereof to acquire Buzz Consolidated Shares in lieu of Novamind Consolidated Shares, and otherwise bearing the same terms as the Novamind Convertible Securities which they replace.

Completion of the Qualifying Transaction is subject to the satisfaction of a number of conditions, including, but not limited to:

Selected Financial Information of Novamind

The following tables sets out unaudited historical financial information of Novamind for the period commencing on its date of incorporation, May 22, 2019 and ending April 30, 2020.

Novamind Financing

In connection with the Qualifying Transaction and prior to the Novamind Consolidation, Novamind is undertaking a non-brokered private placement (the Financing) of Novamind Shares at a price of $0.10 per share for minimum gross proceeds of $2,500,000. Novamind engaged First Republic Capital Corporation (First Republic) as its exclusive lead finder in connection with the Financing. As compensation, First Republic will be paid a cash commission equal to 7% of the aggregate gross proceeds of the Financing and compensation warrants (Compensation Warrants) equal to 7% of the number of Novamind Shares issued under the Financing. Each Compensation Warrant entitles the holder to acquire a Novamind Share at an exercise price of $0.10 for a period of 24 months following the closing date of the Financing. The Novamind Consolidation will result in the number of Novamind Shares and Compensation Warrants issued in the Financing being divided by four, and the effective offering price under the Financing and the exercise price of the Compensation Warrants being adjusted to $0.40 per share. Novamind has closed a first tranche of the Financing for gross proceeds of $1,607,500.

Pro Forma Capitalization

The table below demonstrates the anticipated non-diluted capitalization of the Resulting Issuer post Qualifying Transaction and Financing, assuming completion of the minimum Financing, and lists the number of common shares of the Resulting Issuer (Resulting Issuer Shares) anticipated to be held by the Buzz Shareholders, Novamind Shareholders and investors in the Financing.

Note:

It is anticipated that proceeds from the Financing will be used for acquisitions and for general working capital.

Board of Directors, Officers and other Insiders

Upon completion of the Qualifying Transaction, it is anticipated that the board of directors and officers of the Resulting Issuer will be comprised of the individuals listed below. In addition, the parties anticipate that Novamind will nominate the Chief Financial Officer and Corporate Secretary of the Resulting Issuer. The identities and biographies of these individuals will be disclosed in a subsequent press release or filing statement prepared in connection with the Qualifying Transaction. To the knowledge of Novamind and Buzz Capital, no person will beneficially own, directly or indirectly, or exercise control or direction over, more than 10% of the Resulting Issuer.

Chuck Rifici (Director), Ottawa, Ontario

Chuck is a pioneer of the North American cannabis industry, having created and managed opportunities which have had an incredible and widespread impact on the Canadian cannabis landscape. The founder of Canopy Growth (FKA Tweed Marijuana), Chuck is Chairman of Auxly Cannabis Group, Chairman at Feather Company and is a chartered professional accountant (CPA). He obtained his MBA from Queens University and holds a BASc in Computer Engineering from the University of Ottawa.

Yaron Conforti (Chief Executive Officer and Director), Toronto, Ontario

Yaron Conforti is the founder and principal of Emmcap Corp., an investor in venture-stage companies. He previously served in senior investment banking roles at Desjardins Securities and Sandfire Securities and in CEO, CFO and corporate director roles for private and public companies.

Jesse Kaplan, CFA (Director), Toronto, Ontario

Jesse Kaplan has been a partner with Plaza Capital Limited since 2015. His career has focused on advising and investing in early stage growth companies. This has included extensive work helping companies through the process of going public in both Canada and the United States. Jesse was previously a senior analyst at Harborview Advisors LLC, a New York based investment firm and Palladium Capital Advisors, LLC, a NASD member investment bank. Currently, he is a board member of Abacus Health Products (CSE:ABCS) among other successful companies.

Sruli Weinreb (Director), Toronto, Ontario

Sruli Weinreb is the founder and managing partner of Plaza Capital Limited. Plaza Capital supports many North American early stage growth companies with strategic debt placements and equity investments. He is also the chief executive officer of Lake Central Air Services Inc., the worlds leading modification and integration partner for the airborne geophysical survey industry. Before founding Plaza Capital in 2013, Sruli was the chief executive officer of eMobile Inc., a telecom arbitrage company with a specialization in international roaming which he co-founded in 2008.

Sponsorship

Sponsorship of a qualifying transaction of a capital pool company is required by the Exchange unless exempt in accordance with Exchange policies. Buzz Capital is currently reviewing the requirements for sponsorship and may apply for an exemption from the sponsorship requirements pursuant to the policies of the Exchange; however, there is no assurance that Buzz Capital will ultimately obtain this exemption. Buzz Capital intends to include any additional information regarding sponsorship in a subsequent press release.

Further Information

The Buzz Shares are currently halted from trading on the Exchange and will remain halted until such time as determined by the Exchange, which, depending on the policies of the Exchange, may or may not occur until the completion of the Qualifying Transaction.

All information contained in this news release with respect to Novamind and Buzz Capital was supplied by the parties respectively, for inclusion herein, and each party and its directors and officers have relied on the other party for any information concerning the other party.

Completion of the transaction is subject to a number of conditions, including, but not limited to, Exchange acceptance and if applicable pursuant to Exchange requirements, majority of the minority shareholder approval.

Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.

The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the intention of the parties to enter into the Definitive Agreement, the completion of the Financing and Amalgamation, listing as an Industrial Issuer, and the use of proceeds from the Financing. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Corporation. The material factors and assumptions include the parties to the Definitive Agreement being able to obtain the necessary director, shareholder and regulatory approvals; Exchange policies not changing; and completion of satisfactory due diligence. Risk factors that could cause actual results or outcomes to differ materially from the results expressed or implied by forward-looking information include, among other things: conditions imposed by the Exchange, the failure to obtain the required directors' and shareholders' approval to the Qualifying Transaction; changes in tax laws, general economic and business conditions; and changes in the regulatory regulation. The Corporation cautions the reader that the above list of risk factors is not exhaustive. The forward-looking information contained in this release is made as of the date hereof and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in theUnited States. The securities have not been and will not be registered under theUnited StatesSecurities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within theUnited Statesor to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

SOURCE: Buzz Capital Inc.

For further information:

Buzz Capital Inc. Chuck RificiCEO, CFO and Director

Tel: (613) 239-0531

Novamind Ventures Inc. Yaron ConfortiCEO and Director

Tel: (647) 953-9512

Website: http://www.novamind.ca

Link:

Novamind and Buzz Capital Announce Qualifying Transaction TSX Venture Exchange:BUZ-P - GlobeNewswire

Revive Therapeutics Provides Corporate Update on its Pharmaceutical Initiatives – GlobeNewswire

Posted on by

TORONTO, May 13, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (Revive or the Company) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide a corporate update on its pharmaceutical programs for Bucillamine in the treatment of the coronavirus disease (COVID-19) and in the psychedelics area.

We are advancing our main programs in COVID-19 and psychedelics with the aim to initiate clinical studies in the short-term while leveraging our assets and building our pharmaceutical-based product pipeline for long-term growth, said Michael Frank, Revives Chief Executive Officer.

Bucillamine in the treatment of COVID-19

The Company is preparing along with its CRO, Pharm-Olam, the Investigational New Drug (IND) package to the U.S. Food and Drug Administration (FDA) for the proposed Phase 3 confirmatory clinical trial (Phase 3 study) to evaluate Bucillamine in the treatment of patients with mild-moderate COVID-19 due to the SARS-CoV-2 infection. As previously announced, the FDA recommended that the Company proceed directly into a confirmatory clinical trial. Also, the Company is updating its current IND with the FDA for Bucillamine, which will not only pave the way to proceed with the Phase 3 COVID-19 study but also the IND will serve as the foundation to pursue future programs with Bucillamine in infectious diseases and inflammatory and respiratory disorders. Revive aims to submit the FDA IND package in June 2020 and expects to obtain FDA acceptance to proceed to a Phase 3 study. The Company is also seeking to conduct a clinical study with Bucillamine in the treatment of COVID-19 in Canada and is preparing its pre-Clinical Trial Application (pre-CTA) package to Health Canada that will include data on the safety, efficacy, manufacturing process and clinical trial protocol of Bucillamine. The Company estimates to have feedback from Health Canada in June 2020 and expects to initiate a clinical study as soon as possible following receipt of regulatory clearance from Health Canada.

Drug Delivery License and Psilocybin Research and Development

Further to the Companys recent announcement in entering into a sponsored research partnership agreement with the University of Wisconsin-Madison to evaluate novel formulations and drug delivery technology focused on psilocybin-based pharmaceuticals, Revive has expanded its exclusive license of the drug delivery technology from the Wisconsin Alumni Research Foundation (WARF) to include all hallucinogenic compounds. The Company has a worldwide license agreement with WARF for the drug delivery technology in the research and development and commercialization of all cannabinoids and hallucinogenic compounds using the drug delivery technology which initially aims to deliver both synthetic and natural extract of psilocybin in a potential number of ways such as topical gels, creams or ointments, oral or transdermal patches, oral dosages and foams. Revive is currently evaluating novel oral dosage forms of psilocybin, such as oral dissolvable thin films or tablets, and is working with the Reed Research Group out of the University of Wisconsin-Madison to complete formulation development with the intent to pursue clinical studies for indications currently not being evaluated with psilocybin. In addition, the Company is exploring opportunities to sponsor an investigator-led clinical trial evaluating psilocybin in the treatment of a particular indication to be disclosed once an agreement has been finalized.

About Revive Therapeutics Ltd.

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza strains including COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revives cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit http://www.ReviveThera.com.

The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (or SARS2 Coronavirus) at this time.

For more information, please contact:Michael FrankChief Executive OfficerRevive Therapeutics Ltd.Tel: 1 888 901 0036Email: mfrank@revivethera.comWebsite: http://www.revivethera.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains forward-looking information within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words could, intend, expect, believe, will, projected, estimated and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revives current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Offering, including the intended use of proceeds. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading Risk Factors in the Companys annual MD&A for the fiscal year ended June 30, 2019, which has been filed on SEDAR and is available under the Companys profile at http://www.sedar.com.

See the original post here:

Revive Therapeutics Provides Corporate Update on its Pharmaceutical Initiatives - GlobeNewswire

Working at AM LLC: Employee Reviews | Indeed.com

Posted on by

Grateful and Excited - Small Business Going Big!

I have worked with AM LLC for the past 6 years as part of the executive management team. This company is founded on and operates based on the values of Integrity, Excellence, Service, Professionalism, Appreciation & Acknowledgement, Generosity, Responsibility, Teamwork, Hard Work, Growth & Development, and Fun. Ideas, goals, questions, comments, and concerns of employees, suppliers, and clients are listened to, discussed, considered and acted upon with a win/win/win attitude. Applied Memetics is committed to providing Quality service to its customers and quality care to its employees. Applied Memetics works on a number of projects with its teaming partners and continues to grow and expand its contribution to its clients, thus providing new opportunities for perspective employees. The executive team maintains an open door policy and is readily available to address any matter brought up by its employees. Performance is rewarded and trust is earned. Honesty, complete and direct communication, forward risked-based thinking, organization, commitment, and perseverance are major contributing factors to this company's success. The virtual nature of the company is not like working in a traditional office setting where employees see each other everyday. It takes some getting used to. But, the virtual atmosphere provides a lot of flexibility and other benefits. Continue to focus on growth and development of employees' skills (technical and leadership) and partnership and work opportunities.

Excerpt from:

Working at AM LLC: Employee Reviews | Indeed.com